# Inborn errors of immunity: manifestation, treatment, and outcome – an ESID registry 1994-2024 report on 30,628 patients

Gerhard Kindle[1, 2, 42], Mickaël Alligon[3, 42], Michael H. Albert[4], Matthew Buckland[5, 6], J. David Edgar[7], Benjamin Gathmann[1], Sujal Ghosh[8], Antonios Gkantaras[9], Alexandra Nieters[1, 2], Claudio Pignata[10], Peter Robinson[11, 12], Stephan Rusch[1, 2], Catharina Schuetz[13, 14], Svetlana Sharapova[15], Benjamin Shillitoe[16], Fabio Candotti[17], Andrew J. Cant[18, 19], Jean-Laurent Casanova[20, 21, 22, 23, 24], Amos Etzioni[25], Alain Fischer[26, 21], Isabelle Meyts[27], Luigi D. Notarangelo[28], Martine Pergent[29], C. I. Edvard Smith[30, 31, 32], ESID Registry Working Party, Lennart Hammarström[33, 43], Bodo Grimbacher[1, 34, 35, 36, 37, 43], Mikko Seppänen[38, 39, 43], Nizar Mahlaoui[3, 40, 43], Stephan Ehl[1, 43], and Markus G. Seidel[41, 43, 44]

1. Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
2. Centre for Biobanking FREEZE, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
3. French National Reference Center for Primary Immune Deficiencies (CEREDIH), Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
4. Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians Universität München, Munich Germany
5. Barts Health National Health Service Trust, London, United Kingdom
6. Molecular and Cellular Immunology Section, Immunity and Inflammation Department, Great Ormond Street Institute of Child Health, London, United Kingdom
7. Department of Immunology, St James's Hospital, & School of Medicine, Trinity College Dublin, Ireland
8. Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University and University Hospital, Duesseldorf, Germany
9. Pediatric Immunology and Rheumatology Referral Center, 1st Department of Pediatrics, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
10. Department of Translational Medical Sciences, Federico II University, Naples, Italy
11. Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Berlin, Germany
12. The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
13. Department of Pediatrics and University Center for Rare Diseases, Medizinische Fakultät Carl Gustav Carus, Technische Universität, Dresden, Germany
14. German Center for Child and Adolescent Health (DZKJ), partner site Leipzig/Dresden, Dresden, Germany
15. Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus
16. Paediatric Immunology and Infectious Diseases, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom
17. Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
18. Translational and Clinical Research Institute, Newcastle University
19. Department of Paediatric Immunology and Infectious Diseases, Great North Children's Hospital, Newcastle upon Tyne, England, UK
20. Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, Paris, France

21. Imagine Institute, University Paris Cité, Paris, France
22. St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
23. Howard Hughes Medical Institute, New York, NY, USA
24. Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France
25. Faculty of Medicine, Technion, Haifa, Israel
26. Unité d'immunologie pédiatrique, Hôpital Necker Enfants Malades, Paris
27. Department of Pediatrics, Department of Microbiology, Immunology and Transplantation, University Hospitals Leuven, KU Leuven, Leuven, Belgium, ERN-RITA Core Center
28. Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
29. International Patient Organisation for Primary Immunodeficiencies (IPOPI), Brussels, Belgium
30. Department of Laboratory Medicine, Clinical Immunology, Karolinska Institutet, Stockholm
31. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
32. Karolinska ATMP Center, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
33. Division of Immunology, Dept of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
34. Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Germany
35. DZIF - German Center for Infection Research, Satellite Center Freiburg, Germany
36. CIBSS - Centre for Integrative Biological Signalling Studies, Albert-Ludwigs University, Freiburg, Germany
37. RESIST - Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Germany
38. Rare Disease Center and Pediatric Research Center, Children and Adolescents, University of Helsinki, HUS Helsinki University Hospital, ERN-RITA Core Center, RITAFIN, Helsinki
39. Translational Immunology Research Program, University of Helsinki, Finland
40. Pediatric Immuno-Hematology and Rheumatology Unit, Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
41. Styrian Children's Cancer Research Unit for Cancer and Inborn Errors of the Blood and Immunity in Children; Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, Medical University of Graz, Graz, Austria
42. *These authors contributed equally and should be considered aequo loco.*
43. *These authors jointly designed, coordinated, and supervised the study.*
44. *Corresponding author: Univ.-Prof. Dr. Markus G. Seidel,* Division of Pediatric Hematology and Oncology, Medical University of Graz, Auenbruggerplatz 38, 8036 Graz, Austria; Email: markus.seidel@medunigraz.at

**Key words:** Inborn error of immunity (IEI); primary immunodeficiency (PID); primary immune disorder (PID); online database; patient registry; overall survival.

**Word count:** abstract: 173; summary: 51; main text: 3463; tables: 1; figures 5; references: 30; supplementary material.

**Conflict of interest** statement at the end of the article.

**ORCID identifiers:** GK ORCID: 0000-0003-0894-5327; MHA ORCID: 0000-0001-9143-3263; JDE ORCID: 0000-0003-2969-4475; AG ORCID: 0000-0003-3609-1824; BS ORCID: 0000-0003-4407-5998; CIES ORCID: 0000-0003-1907-3392; MGS ORCID: 0000-0003-0981-8661.

# Abstract

The *European Society for Immunodeficiencies* patient registry (ESID-R), established in 1994, is one of the world's largest databases on inborn errors of immunity (IEI). IEI are genetic disorders predisposing patients to infections, autoimmunity, inflammation, allergies and malignancies. Treatments include antimicrobial therapy, immunoglobulin replacement, immune modulation, stem cell transplantation and gene therapy. Data from 194 centers in 33 countries capture clinical manifestations and treatments from birth onward, with annually expected updates. This report reviews the ESID-R's structure, data content, and impact.

The registry includes 30,628 patient datasets (aged 0–97.9 years; median follow-up: 7.2 years; total 825,568.2 patient-years), with 13,550 cases in 15 sub-studies. It has produced 84 peer-reviewed publications (mean citation rate: 95). Findings include real-world observations of IEI diagnoses, genetic causes, clinical manifestations, treatments, and survival trends. The ESID-R fosters global collaboration, advancing IEI research and patient care. This report highlights the key role of the multi-national ESID-R, led by an independent medical society, in evidence-based discovery.

## Summary

Worldwide, most patient registries for inborn errors of immunity are national, with limited geographical and temporal scope. This 30-year ESID registry analysis of 30,628 patients' longitudinal datasets enables robust epidemiological studies on natural disease courses including diagnosis, treatment, and survival, supporting expanded newborn screening and future AI applications in IEI research.

# Introduction

Inborn errors of immunity (IEI) are genetic disorders affecting immunity. They almost invariably increase the susceptibility to infections and may cause autoimmunity, inflammation, allergy, and predispose individuals to malignancy(1-6). IEI can manifest at any age and are characterized by a spectrum of symptoms related to impaired or uncontrolled immune responses. These often have a serious impact on the health and quality of life of those affected. Many IEI are rare diseases, including ultra-rare and hyper-rare forms (*i.e.*, frequently <<1/2000 persons affected). Thus, an international strategy was needed to collect a meaningful number of datapoints for cross-sectional analyses and longitudinal clinical observations of natural courses of specific IEI.

The *European Society for Immunodeficiencies* registry (ESID-R) was founded in 1994 by ESID, a non-profit medical specialist society, creating a central database for primary immunodeficiencies. These are currently referred to as IEI or primary immune disorders (PID), differentiating them from secondary immune disorders (SID)(7). The ESID-R mainly serves to contain, store, and enable the analysis of IEI/PID data to improve the understanding of these diseases and their underlying immunobiology. Historically, the ESID-R was operated for the first 10 years as a hard copy-based database, and data were submitted by fax to the first chairs of the ESID-R, Lennart Hammarström and Mohammad Abedi in Huddinge, Sweden. From 2000–2004, Bodo Grimbacher with coworkers in Freiburg, Germany, developed and implemented the first web-based version of the ESID-R(8 9). In 2014, another major revision was carried out, headed by Stephan Ehl, Freiburg. The two key drivers of this second re-design were the goal to allow registry participation at three different levels according to center resources and the need to improve data quality so that a high level of confidence in the accuracy of the data could be inferred for clinical application and publication. In addition to inbuilt quality checks, the migration of existing data to the third version of the ESID-R and the entry of new patient data since then required a manual validation process of all included patients lacking a genetic diagnosis to meet the simultaneously developed clinical working criteria for IEI/PID diagnoses, compiled and published by a group of experts(10). In late 2024, ESID decided to move the ESID-R technical and physical foundation from the Medical Center of the University of Freiburg to a commercial clinical trials operator (Castor-edc, NL) to improve data-, system-, and access security. Maintaining the three-level study structure and the mandatory diagnosis validation process, this currently new, fourth version of the ESID-R is expected to facilitate the generation of data modules by research groups, allowing decentralized sub-study (eCRF) programming, independent data exports for center or sub-study analyses, automated center dashboards and add-on features such as patient reporting.

Here, we present major findings from clinical observations of 30,628 patients, based on the current ESID-R dataset. These findings indicate epidemiologically relevant disease distributions and the calculated prevalence of diagnoses in registered patients, their clinical manifestations, diagnostic delays, treatment, disease course and survival probabilities across all IEI/PID categories. Furthermore, we describe the organizational and technical evolution of the ESID-R, its relationship with the international registry landscape, and its role as a research (sub-)study platform. These data are of the utmost relevance to anyone affected by immune disorders or involved in patient care, management and therapy, drug and policy development for patients with IEI/PID around the world.

# Methods

## Technical background and operating mode of the ESID-R

The study protocol, the patient informed consent template and the center data transfer agreement plus amendments thereof were approved by the IRB and the data protection officer at the Medical University of Freiburg, Germany (Albert-Ludwigs-University). A substantial amendment was approved by the Medical University of Graz, Austria (24-334 ex 11/12, IRB00002556) and implemented in 2024. Details of the operational structure and technical background are found in the *Supplementary Material*.

## Data and statistical analyses

The study population included all patients with IEI/PID recorded in the ESID-R on March 19, 2024. Patients considered as discharged (*n*=538), patients with secondary immunodeficiency who were documented as part of one national subregistry only (*n*=417), or without definitive IEI diagnosis (n=306) were excluded from the study, leaving 30,628 patients. IEI were classified using the latest classification of the *International Union of Immunological Societies* (IUIS)(6), with abbreviations of the category names using, *e.g.*, "PIRD", typically referred to as primary immune regulatory diseases, as synonym for "Diseases of immune dysregulation" (category *IV*; *i.e.*, including familial hemophagocytic lymphohistiocytosis, FHL). The statistical analyses were conducted using R (version 4.3.2, Vienna, Austria). Continuous and categorical variables were reported using the medians and interquartile ranges, raw effectives, and percentages, respectively. Survival probabilities were estimated by applying the cumulative incidence function. Overall survival (OS) was defined as the time between birth and death from any cause. Curative therapies, such as allogeneic hematopoietic stem cell transplantation and gene therapy, were considered as competing events. Survival was analyzed using the R package *survival* version 3.8-3 as described previously(11). As only patients with an eligible diagnosis are included, they are not considered to be at risk of dying before they are diagnosed(11). The prevalence was calculated based on the European population in 2019 (R package *rnaturalearth* version 1.0.1).

## Role of the funding source

The present and former funding entities of ESID (*i.e.*, Plasma Protein Therapeutics Association [PPTA] Europe [Baxter, Biotest, Grifols, Kedrion, Octapharma], Novartis, UCB, Celltech, GSK, Pharming, Takeda [and corporate predecessors] and Chiesi) had no role in the study design, study conduct, data collection, data management, data analysis, data interpretation, or writing of this report.

# Results

On the end date chosen for inclusion, the ESID-R contained data for 30,628 IEI/PID patients from 194 participating centers in 33 European and other, mostly neighboring countries. There was a steady increase in the registration of patients over time (supplementary figure 1) apart from a temporary decline in patient numbers and, to a lesser extent, in center numbers shortly after 2014, due to structural platform changes in 2014. These required centers to verify their patients to improve the accuracy of existing data. This allowed us to derive patient distribution by country and the minimal prevalence of PID/IEI (supplementary table 1 and supplementary figure 2).

## Patient characteristics

Figure 1 shows the ages at onset, clinical and genetic diagnoses and main clinical manifestations that led to diagnosis. A steady decline in new diagnoses was observed with age, although a small second peak and plateau were seen in adulthood, and a trend for earlier identification of genetic diagnoses was observed. The delay from the onset of symptoms to clinical diagnosis and between clinical and genetic diagnosis is shown by year of clinical or genetic diagnosis, *i.e.*, the endpoint of each delay, over the last 20 years in supplementary figure 1C. As reported previously(12), the majority of 80.3% of patients have infections on their way to diagnosis, but only in 61.8% as sole recorded manifestation of IEI, followed by features of immune dysregulation in 11.1% and syndromic manifestations in 7.3% as sole clinical presentation at diagnosis (*n*=15,360; 2,746; 1,803, respectively; figure 1B). Malignancies were among the first manifestations of IEI in 479 patients, and the only initial manifestation in 117 patients (0.5%; figure 1B).

Table 1 shows the main patient demographic and diagnosis categories, comorbidities such as malignancy, COVID-19 and living status. The interactive supplementary figure 3 shows the patient numbers and their distribution according to their IUIS classification, disease name, and genetic diagnosis (https://esid.org/html-pages/Suppl%20Fig%203_ESID_30k_sunburst_PID.html). About half of all patients suffer from primary antibody deficiencies (PAD; *n*=15,123), followed in descending order, by combined immunodeficiencies with syndromic features ("syndromic"; *n*=4,239), phagocytic disorders ("phagocyte"; *n*=2,548), combined immunodeficiencies (CID; *n*=2,531), and primary diseases of immune dysregulation (PIRD; *n*=2,171; table 1 and supplementary figure 3). Table 1 presents the ages at onset, clinical diagnosis, genetic confirmation, and last follow-up, and the diagnostic delay. The proportion of patients reported to have suffered from malignancies was 8.9% (*n*=1,783). Malignancies were reported as occurring in all subgroups of patients with IEI/PID with moderately varying frequencies, corroborating the notion that IEI/PID are cancer predisposition syndromes. The proportion of patients reported to have been affected by COVID-19 was highest in PAD (35.9%; total cohort: 29.7%). More than half of CID patients received curative therapy (52.6%), followed by those with bone marrow failure syndromes (BMF; 39.8%), PIRD, and phagocyte disorders (30.3 and 25.8%, respectively). Supplementary Table 2 shows the causes of death.

## Representation of genetic IEI diagnoses

Figure 2 shows the absolute numbers of patients with a documented genetic diagnosis (*n*=12,774, 44.5%,*)* versus those without (*n*=15,905, 55.5%, including patients not genetically tested) by IEI category. As expected, within the largest patient subgroup (PAD), the genetic diagnosis is lacking for the majority of patients (figure 2A) and the clinical diagnosis of CVID is attributed, whereas patients with CID with syndromic features had the highest proportion of genetic diagnoses. The top five genes mutated per IEI category are shown in figure 2B, with *IL2RG* being the most frequently reported germline genetic cause of CID; *22q11.2 deletion syndrome,* of CID with syndromic features; *BTK*, of PAD; *TNFRSF6*, of category IV, diseases of immune dysregulation; *CYBB*, of phagocyte disorders; *STAT1*, of intrinsic or innate immune disorders; *MEFV*, of autoinflammatory syndromes; C1 inhibitor, of complement deficiencies; *RTEL*, of BMF; and somatic *TNFRSF6*, of phenocopies. The top 50 genetic causes of IEI from the ESID-R are shown with patient numbers in descending order in supplementary figure 4.

## Treatment modalities according to IEI categories

Immunoglobulin replacement therapy (IGRT), hematopoietic stem cell transplantation (HSCT), gene therapy (GT), and splenectomy are recorded in the ESID-R and listed in supplementary table 3. As expected, the highest number and proportion of IGRT-receiving patients is seen in the subgroup of patients with PAD (figure 3). The highest absolute numbers of HSCT procedures were performed in patients with CID, followed by those with PIRD and phagocytic disorders. IGRT and HSCT were documented in patients with IEI/PID in any category. Gene therapy, an evolving curative treatment option devoid of some risks associated with HSCT, such as alloreactivity, was recorded in a descending order for CID, syndromic and phagocyte disorders (figure 3). Splenectomy was recorded relatively frequently in patients with phenocopies, but it was also documented for any IEI category. The use of immune-modulatory treatments such as anti-inflammatory, cell-depleting, or pathway-directed (targeted) therapies and the rare cases of thymus or solid organ transplantation were recorded but are not shown here, as the heterogeneity of the data exceeds the scope of this general report.

## Survival probabilities of patients with IEI

We hypothesized that the survival probabilities of patients in the 10 IUIS categories of IEI differed due to their varying predispositions to life-threatening infections, malignancies, autoimmunity, or other manifestations and complications associated with their underlying conditions. Although the data granularity in the entire ESID-R with respect to patient follow-up intervals is not comparable with that in disease-specific prospective cohort studies, we could plot the reversed cumulative incidence function, due to the presence of competing risks, based on the relatively large patient numbers in each IEI category (figure 4; see supplementary figure 5 for the same curves with confidence intervals). Of note, natural biases such as underreporting of patients who died from IEI before diagnosis or of patients with a mild phenotype exist, and numbers at risk increased over the first few years of the observation period (0–97.9 years of age) due to the later time points of inclusion or diagnosis. We detected a steep early decline in survival in many IE categories while

curves plateaued, *i*, methodologically, in some where definitive treatments exist, or, *ii*, in genotypes with variable penetrance (*e.g.*, CID, PIRD). Additionally, while patients with PAD showed a continuous decline in survival probability from a young age across all age groups, the decline in the survival of patients with phagocyte and innate immune disorders showed an initial drop. This finding suggests that a proportion of patients are at very high risk during their first five years of life. Diagnoses of early deceased patients with PIRD (n=70 under 5 years of age) were mostly due to disorders with a high risk of hemophagocytic lymphohistiocytosis (HLH; 81.4%); premature deaths in "innate" IEI were frequently due to IRAK4 or MyD88 deficiencies (supplementary table 4). Patients with IEI/PID with syndromic features had a triphasic survival probability. After observing an initial decline in the first four years of life, we detected a second pronounced decline in survival probability in the patients' 2$^{nd}$ and 3$^{rd}$ decades of life, most likely due to the increased risk of malignancies in many patients in this subgroup (>25%, see supplementary table 2), and a third, relatively steep decline in patients in their 6$^{th}$–7$^{th}$ decades.

## The ESID-R in the international data source landscape

Other continental or cross-regional IEI/PID registries of varying temporal and geographical depth include the global *Jeffrey Modell Foundation* Centers Network (>94,000 patients), the *USIDNET* registry in the USA (>5,000), the *LASID* registry in Latin America (>9,000), the Australian *AusPIPS* registry (>1,500) as part of the Australasian network, *JSIAD* (>1,200) in Japan as part of the Asian-Pacific (APSID) network, the Canadian registry (*CIEINR*) founded in 2024 and the registries of the *Primary Immune Deficiency Treatment Consortium (PIDTC)* of North America; in addition, many national registries exist inside or outside of ESID(13). Those reported in Europe are shown in supplementary figure 7. Furthermore, the ESID-R is listed as official data source in catalogues of EMA, the European Medical Agency, and of ERDRI, the EU rare disease platform, which are metadata repositories to increase visibility and facilitate the use of rare disease patients' data.

## Scientific impact of the ESID-R and sub-studies

Up to the end date chosen for data inclusion in this manuscript, 84 peer-reviewed publications resulted from projects deriving data directly from the ESID-R (Figure 5 and ESID website(14)). We evaluated this scientific output by categorizing and counting the publications and their citations as follows: disease-specific natural history studies (*n*=25; 3,658 citations), country-specific epidemiological studies (*n*=19; 2,575 citations), six reviews (422 citations), two on technical aspects (104 citations) and 15 of our own registry-conducted studies (*e.g.*, on first manifestations or on working definitions for the clinical diagnosis of IEI/PID, 1,221 citations), plus 17 studies that could have been assigned to multiple or overlapping categories (figure 5), resulting in a mean citation rate of 95 per publication.

# Discussion

The ESID-R is a large and growing real-world database enabling powerful analyses that have continuously generated epidemiological and disease-specific observational results since 1994. It contributes to knowledge and improvements in patient care in IEI in Europe and beyond. The present analysis illustrates the current distribution of: *i)* IEI diagnoses recorded in contributing centers and countries, *ii)* major treatment modalities between all IEI categories, *iii)*, ages at onset, at clinical and at genetic diagnosis and *iv)* survival probabilities. Our results underline the recommendation to implement newborn screening, potentially even for certain additional IEI other than severe combined immunodeficiencies (SCID). The 7,980 citations of 84 peer-reviewed ESID-R-based publications as of early 2024 demonstrate the success of the ESID-R as platform for research sub-studies and their substantial scientific impact. Hence, the ESID-R provides a clear example of how data collection and collaboration can benefit patients with rare diseases.

## Survival probabilities, early diagnosis, and newborn screening

Newborn screening (NBS) for SCID by measuring T-cell receptor with or without kappa-deleting recombination excision circles in dried blood spots has been implemented in many countries around the world(15-17). A substantial survival benefit for patients diagnosed and treated by early HSCT was demonstrated and recently confirmed in a longitudinal study of the PIDTC(18). The steep early decline in survival we observed in patients with disorders of immune regulation and “innate” IEI may argue for an extension of NBS to other immediately life-threatening IEI (*e.g.*, FHL, XLP1, MyD88/IRAK4 deficiencies and IPEX syndromes). To extend the spectrum of early IEI–NBS, current techniques may be supplemented by RNA sequencing or germline genetic testing, such as targeted sequencing panels, whole exome or genome sequencing. Feasibility studies of such extended NBS are ongoing in regional or national programs(19). However, the vast ethical and social implications of any omics-based addition like baby genome screening will require careful consideration of the risks and benefits(20).

## Methodological and organizational limitations

Physicians and other documentarists regularly collect data for the ESID-R on a voluntary basis, with data quality and quantity (*i.e.*, data depth and accuracy) varying substantially between centers and across countries. Depending on resources dedicated to data documentation, an underestimation of the prevalence of IEI/PID, assumed to be widely similar across Europe, of around 30% was demonstrated(21). While all centers can participate in the ESID-R and scientific sub-studies for free, minimum infrastructure is required. With the rare exception of per-patient fees in pharma-sponsored level-3 studies, ESID does not financially reimburse data entry. The participants mainly benefit from the international academic collaboration and representation, which increases their awareness for disease phenotypes and current clinical research questions. Also, each center may obtain their own (local and regional) epidemiological data within a legally and ethically approved and financially sustainable technical framework (see survey results in the supplementary material). Furthermore, ESID has no means of monitoring the data quality other than by inbuilt checks for logic and completeness at the time point of data entry. So far, automated transfers of data from

electronic health records (eHR) into the ESID-R, which have the potential to overcome many of the aforementioned obstacles and to enhance both the quality and quantity of recorded data, have not been attempted due to regulatory obstacles and the heterogeneity of eHRs in the 194 participating centers. All the above, along with the fact that some monogenic IEIs have only been described recently while others have been recognized for decades, introduces a systemic ascertainment bias into the dataset when comparing, *e.g.*, numbers of diagnoses and time of survival. For example, X-linked agammaglobulinemia (caused by mutations in *BTK*)(22) is probably not eight times more prevalent than, *e.g.*, the autosomal-dominant CTLA4-(haplo)insufficiency(23 24) or NFKB1-(haplo)insufficiency(25). In summary, we build on the trust of participants and the success of this huge cooperative effort, to continue the ESID-R in its fourth technical version starting from late 2024, serving as up-to-date simple and free platform for inherently motivated international scientific clinical research collaboration.

## Challenges of reporting genetic data

Collecting data from the heterogenous patient population of individuals with IEI/PID and storing these in a registry presents many challenges. Scientists estimate that current routine next-generation sequencing (NGS) technologies can reveal a molecular cause in approximately 30–35% of IEI cases(19). It is noteworthy that information classifying detected variants by applying ACMG criteria or performing functional validation is not collected in the ESID-R. Phenotype information derived from the ESID-R might support the efforts of the *ClinGen Immunology Gene and Variant Curation Expert Panels*(26). The incorporation of genetic data beyond known pathogenic mutations, ideally linked to precisely defined phenotypes according to the human phenotype ontology (HPO)(27), represents a biologically interesting, future challenge. This includes the verification of variants of unknown significance, intronic changes, somatic mutations and mosaicism, epigenetic factors, variable penetrance and other less-studied factors as non-coding modifier alleles and monoallelic expression(28).

## Link to other registries, synergies, overlapping efforts

From a scientific perspective, it has become increasingly important to compare outcomes for IEI/PID patients with and without cellular therapy (HSCT or gene therapy). The registry of the *European Society for Blood and Marrow Transplantation* (EBMT) currently registers definitive cellular therapies in about 700 patients with IEI per year(29), many of whom are also registered in the ESID registry. Hence, to optimize future research, datasets from the ESID and the EBMT registries for the same patients should be combined. Better alignment of the registries and their data fields is urgently needed to facilitate such studies, and we expect the new technical platform to facilitate data exports and imports alike across providers. Furthermore, the IUIS classification has gradually incorporated more diseases from overlapping specialties (*e.g.,* hematology-oncology, rheumatology, gastroenterology), many of which are (also) covered by other medical societies and patient registries. Thus, although data from many of these patients are stored in the ESID-R, their proportion in the ESID-R does not reflect the real-world distribution. The registry of the *European Reference Network for Rare Immunological and Autoimmune Diseases (ERN-RITA)*, an EU sponsored network of healthcare providers from reference centers for PID/IEI, rheumatology, autoinflammatory and

371 autoimmune diseases, aims to collect common data elements from patients across these disease
372 areas. This initiative may help to avoid redundancy. Finally, using independent (meta-)identifiers
373 such as the *European SPIDER-ID(30)* in all registries would help scientists disentangle the registry
374 landscape.

## 375 Future: AI in registry work for data analysis and interpretation

376 Advanced software tools and artificial intelligence (AI, *e.g.*, large language models, natural language
377 processing, and machine learning), will certainly transform clinical decision-making and other crucial
378 processes in medicine including the field of IEI.(31 32) Automated eHR scanning and data harvesting
379 processes, ideally for specific terms in accordance with HPO, medical reports, disease classification
380 codes (*e.g.*, ICD-11 or ORPHA codes), but also for free text may be used to identify currently
381 undiagnosed IEI/PID patients. These individuals might benefit from early screening by preventing
382 complications. Accordingly, as a first step, data from an IEI/PID registry like the ESID-R that includes
383 data from patients with an established diagnosis could be used to train AI models and to predict a
384 monogenic IEI or at least the most likely affected pathway in patients who lack a genetic diagnosis.
385 Consequently, patients may undergo screening for disease-specific risks and receive appropriate
386 therapy early in their course. In addition to AI-assisted automated data extraction from eHRs to feed
387 patient registries with structured information, complementing the ESID-R with AI-based tools has
388 the potential to transform this data-collection platform to an electronic IEI/PID patient management
389 assistant in the future.

## 390 Conclusions and Perspectives

391 The rarity and complexity of many IEI grants them an orphan status regarding pharmaceutical
392 research and development. The feasibility of clinical research, including drug trials and post-
393 authorization efficacy and safety studies, thus depends on large networks of academic institutions
394 and medical specialist societies. As one of the largest registries, containing extensive longitudinal
395 datasets and having a pan-European reach, the ESID-R is likely to remain one of the most relevant
396 scientific registries for patients with IEI.

## Acknowledgements

The authors would like to thank all contributors and supporters not already mentioned among the collaborator list of the ESID-R working party (*e.g.*, documentarists, study nurses, data analysts) for their continuous support. Scientific language editing was performed by Dr. Sara Crockett, Graz, Austria (www.saras-science.com). MGS was in part funded by the Styrian Children's Cancer Aid Foundation (Steirische Kinderkrebshilfe). MHA represents the PID stream of the European Reference Network for Rare Immunological and Autoimmune Diseases (ERN-RITA). CEREDIH thank colleagues from Université de Paris, Imagine Institute, Data Science Platform, INSERM UMR 1163, F-75015, Paris, France for their contribution in the interface between ESID-R and the CEREDIH registry. LDN is supported by the Division of Intramural Research, NIAID, NIH. IM is a senior clinical researcher at FWO Vlaanderen.

## Conflict of interest statement

MGS received advisory board honoraria from Pharming. MHA received research support, consulting fees, and speaker honoraria from Octapharma. GK, FC declare no conflict of interest. LRD KU Leuven receives research funding and advisory board honoraria for IM from CSL-Behring and Boehringer-Ingelheim. BS has received travel grants from Pharming, and speaker honoraria from Takeda.

## Contributors' statement

MGS designed the study; MGS and GK wrote the manuscript with contributions from MHA, BG, SG, CS, SE, NM, FC, JLC, LDN, CIES; CS, SS and MP collected data about the global registry landscape; AG performed literature search and analyzed ESID-R-related publication records; MA, MGS and GK analyzed the data and prepared the figures. These and all other authors contributed in varying proportions to the technical, organizational, or structural basis of ESID and the ESID-R and to the collection of patient data. All co-authors contributed to and edited drafts of the original manuscript and figures, and approved the final version.

## List of collaborators (ESID registry working party)

Last name, first name: Abd Elaziz, Dalia; Abdelkader, Sohilla Lofty M.; Abitbol, Avigaelle; Abolhassani, Hassan; Abrahim, Lalash; Abuzakouk, Mohamed; Achir Moussouni, Nabila; Afonso, Veronica; Agyeman, Philipp; Ahlmann, Martina; Aiuti, Alessandro; Akl, Abla; Aksu, Güzide; Albers, Kim; Alecsandru, Meda Diana; Aleinikova, Olga; Aleshkevich, Svetlana; Allende, Luis; Allwood, Zoe; Alsina, Manrique de Lara Laia; Ambrosch-Barsoumian, Daniela; Ameshofer, Lisa; Amour, Kenza; Anadol, Evrim; Ananthachagaran, Ariharan; Andriamanga, Chantal; Andris, Julia; Andritschke, Karin; Angelini, Federica; Ankermann, Tobias; Apel, Katrin; Arami, Siamak; Ardeniz, Ömür; Arkwright, Peter; Arnold, Karina; Ascherl, Rudolf; Assam, Najla; Assia-Batzir, Nurit; Atschekzei, Faranaz; Aumann, Sybille; Aumann, Volker; Aurivillius, Magnus; Ausserer, Bernd; Avcin, Tadej; Aydemir, Sezin; Aygören-Pürsün, Emel; Ayvaz Deniz, Cagdas; Azzari, Chiara; Bach, Perrine; Bachmann, Sophie; Bader, Peter; Bakhtiar,

Shahrzad; Bancé, Renate; Bangs, Catherine; Barfusz, Katerina; Baris, Safa; Barlan Isil, B; Bartsch, Michaela; Baumann, Helge; Baumann, Ulrich; Baumeister, Veronika; Baxendale, Helen; Bazen, Suzanne; Beaurain, Beatrice; Beauté, Julien; Bechar-Makhloufi, Mounia; Beck, Norbert; Becker, Brigitta; Becker, Christian; Behrends, Uta; Beider, Renata; Beier, Rita; Belkacem, Amel; Belke, Luisa; Bellert, Sven; Belohradsky, Bernd H.; Ben Slama, Lilia; Ben-Bouzid, Aouatef; Benoît, Vincent; Berdous-Sahed, Thamila; Bergils, Jan; Berglöf, Anna; Bergman, Peter; Bernat-Sitarz, Katarzyna; Bernatoniene, Jolanta; Bernatowska, Ewa; Bernbeck, Benedikt; Bethune, Claire; Beuckmann, Kai; Bhole, Malini; Biegner, Anika-Kerstin; Bielack, Stefan; Bienemann, Kirsten; Bigl, Arndt; Bigorgne, Amélie; Bijl, Marc; Binder, Nadine; Bitzenhofer-Grüber, Michaela; Blanchard Rohner, Geraldine; Blank, Dagmar; Blattmann, Claudia; Blau, Julia; Blaziene, Audra; Blazina, Stefan; Blume, Roswitha; Boardman, Barbara; Bode, Sebastian; Boelens, Jaap-Jan; Boesecke, Christoph; Bogaert, Delfien; Bogner, Johannes; Bohynikova, Nadezda; Booth, Claire; Bordon, Victoria; Borkhardt, Arndt;Börries, Melanie; Borte, Michael; Borte, Stephan; Bossaller, Lukas; Bossard, Madeleine; Botros, Jeannet; Boucherit, Soraya; Boutros, Jeannette; Boyarchuk, Oksana; Boyman, Onur; Boztug, Kaan; Braschler, Thomas; Bravo, Sophie; Bredius, Robbert; Bright, Philip; Brito de Azevedo Amaral, Carolina; Brodszki, Nicholas; Brodt, Grit; Brolund, Allan; Brosselin, Pauline; Brummel, Bastian; Brun-Schmid, Sonja; Brunner, Jürgen; Bruns, Roswitha; Buchta, Christina; Buck, Dietke; Bücker, Aileen; Bührlen, Martina; Burdach, Stefan; Burns, Siobhan; Burton, Janet; Caminal, Luis; Cancrini, Caterina; Canessa, Clementina; Cantoni, Nathan; Capilna, Brindusa; Caracseghi, Fabiola; Caragol, Isabel; Carbone, Javier; Carrabba, Maria; Chamberlain, Latanya;Chandra, Anita; Chantrain, Christophe; Chapel, Helen; Chassot, Julie; Chee, Ronnie; Chinello, Matteo; Chopra, Charu; Chovancova, Zita; Christmann, Martin; Chrzanowska, Krystyna; Ciznar, Peter; Claes, Karlien; Classen, Carl Friedrich; Classen, Martin; Cochino, Alexis-Virgil;Condliffe, Alison M.; Corbacioglu, Selim; Cordeiro, Ana Isabel; Cordier Wynar, Donatienne; Core, Claire; Costes, Laurence; Coulter, Tanya; Courteille, Virginie; Cristina, Maria; Cucuruz, Maria; Dabrowska, Leonik Nel; Dähling, Mandy; Daly, Mary Louise; Daniel, Claudia-Sabrina; Danieli, Maria Giovanna; Darroch, James; Davies, Graham; de Baets, Frans; De Boeck, Christiane; De Gracia Roldan, Javier; de Nadai, Narimene; de Schutter, Iris; De Vergnes, Nathalie; de Vries, Esther; de Witte, Josine ; Debert, Theo; Defila, Corina; Deimel, Judith; Delaplace, Diane; Dellepiane, Rosa Maria; Dellert, Nelli; Delliera, Laura; Delor, Anita; Demel, Ulrike; Dempster, John; den Os, M.M.; Dengg, Rosmarie; Desisa, Sora Asfaw; Desta, Alexandra; Detkova, Drahomira; Dewerchin, Maite; Dieli Crimi, Romina; Dilloo, Dagmar; Dimitriou, Florentia; Dinser, Jasmin; Dipani, Nabila; Dirks, Johannes; Dittrich, Anna-Maria; Djermane, Lylia; Dogru, Yagmur; Dogu Esin, Figen; Dombrowski, Angelika; Döring, Michaela; Drabe, Camilla Heldbjerg; Drerup, Susann; Drexel, Barbara; Driessen, G.J.A.; Dückers, Gregor; Dudoit, Yasmine; Duppenthaler, Andrea; Ebetsberger-Dachs, Georg; Ecser, Mate Barnabas; Eekman, Maartje; Ehrat, Rosanna; Eisl, Eva; Ekwall, Olov; El Hawary, Rabab; El-Helou, Sabine M.; El-Marsafy, Aisha; Elbe, Sarina; Elcombe, Suzanne; Eldash, Alia; Eldeen, Youssif Alkady Radwa Salah; Ellerbroek, P.M.; Elling, Roland; Elliott, Jane; Engelhardt, Angelika; Ernst, Diana; Ersoy, Fügen; Esper, Stefanie; Esteves, Isabel; Exley, Andrew; Faber, Martin; Fabio, Giovanna; Fahrni, Gaby; Faletti, Laura Eva;Faletti, Laura Eva; Farber, Claire-Michele; Farela Neves, João ; Faria, Emilia; Farkas, Henriette; Farmaki, Evangelia; Faßhauer, Maria; Fasth, Anders; Fätkenheuer, Gerd; Faustmann, Stefanie; Fecker, Gisela; Feighery, Conleth; Feiterna-Sperling, Cornelia; Fernandez-Cruz, Perez Eduardo; Ferreira Concalo, Cordeiro; Ferster, Alice; Feuchtinger, Tobias; Feyen, Oliver; Finke, Daniela; Fitter, Sigrid; Flaschberger, Stefan; Fleckenstein, Lucia; Föll, Dirk; Fontana, Adriano; Forino, Concetta; Förster-Waldl, Elisabeth; Franchet, Nora; Freitag, Dagmar; Frey, Urs P.; Friedel, Elisabeth; Friedrich, Wilhelm; Frisch, Barbara; Frischknecht, Lukas; Fritzemeyer, Stephanie; Gagro, Alenka; Gahr, Manfred; Gambineri, Eleonora; Gamper, Agnes; Gams, Franziska; Ganzow, Astrid; Garcelon, Nicolas; Garcez, Tomaz; Garcia Prat, Marina; Gardulf, Ann; Garibay, Janine; Garwer, Birgit; Gathmann, Jonathan; Gebauer, Corinna; Geberzahn, Linda; Geikowski, Tilman; Geisen, Ulf; Gemander, Christiane; Gennery, Andrew R.; Gerisch, Marie; Gernert, Michael; Gerrer, Katrin; Gerschmann, Stev; Giannini, Carolin; Gil Herrera, Juana; Girndt, Matthias; Girrbach, Ramona; Girschick, Hermann; Gkougkourelas, Ioannis; Gładysz, Dominika; Gnodtke, Elisabeth; Goda, Vera; Goddard, Sarah; Goebel, Daniela; Goffard, Jean-Christophe; Goldacker, Sigune; Gollowitsch, Eva Maria; Gomes, Manuella; Gompels, Mark; González, Míriam; Gonzalez Granado, Luis Ignacio; Gordins, Pavels; Gößling, Katharina; Göschl, Lisa; Gossens, Lucy; Gowin, Ewelina; Graafen, Lea; Graca, Leo; Gradauskiene (Sitkauskiene),

Brigita; Graf, Dagmar; Graf, Norbert; Grange, Elliot; Grashoff, H.Anne; Greil, Johann; Grigoriadou, Sofia; Gronlund, Helen; Groß-Wieltsch, Ute; Guerra, Teresa; Guevara-Hoyer, Kissy; Gueye Mor, Seny; Guibert, Noemie; Gülnur, Birgit; Güngör, Tayfun; Guseva, Marina; Guzman, David; Haag, Marcel; Haase, Gabriele; Haenicke, Henriette; Haerynck, Filomeen; Hafsa, Ines; Hagin, David; Hallek, Michael; Hancioglu, Gonca; Handgretinger, Rupert; Hanitsch, Leif G.; Hansen, Susanne; Hariyan, Tetyana; Harrer, Thomas; Hassunah, Pia; Hatzistilianou, Maria; Hauck, Fabian; Hauser, Thomas; Haverkamp, Margje H.; Hayman, Grant; Heath, Paul; Hedrich, Christian; Heeg, Maximilian; Heike, Michael; Heimbrodt, Martin; Heine, Sabine; Heininger, Ulrich; Heinrich, Christian; Heinz, Valerie; Heitger, Andreas; Helbert, Matthew; Helbling, Arthur; Hellige, Antje; Hempel, Julya; Henderson, Karen; Henes, Jörg; Henneke, Philipp; Hennig, Christian; Henrichs, Karin; Herbst, Martin; Hermann, Walter; Hernandez, Manuel; Hernández, Anja; Heropolitanska, Edyta; Herriot, Richard; Herrmann, Friedrich; Herwadkar, Archana; Hess, Christoph; Hess, Ursula; Hesse, Sebastian; Higgins, Sonja; Hilfanova, Anna; Hilpert, Sophie; Hintze, Chantal; Hlaváčková, Eva; Hodl, Isabel; Hodzic, Adna; Hoernes, Miriam; Hoffmann, Christina; Holbro, Andreas; Höllinger, Christiane; Holtsch, Lisa; Holzer, Ursula; Holzinger, Dirk; Hönig, Manfred; Hönscheid, Andrea; Horn, Julia; Horneff, Gerd; Hoyoux, Claire; Hristova, Nataliya; Hübel, Kai; Hübner, Angela; Huemer, Christian; Huissoon, Aarnoud; Hülsmann, Brigitte; Hundsdörfer, Patrick; Huppertz, Hans-Iko; Huß, Kristina; Hussain, Sadia; Husson, Julien; Hüttner-Foehlisch, Tanja; Ijspeert, Hanna; Ikinciogullari, Aydan; İlknur, Kökçü; Irga, Ninela; Jablonka, Alexandra; Jahnz-Rozyk, Karina; Jakob, Marcus; Jakoby, Donate; Jandus, Peter; Jansson, Annette; Jaquet, Melanie; Jardefors, Helene; Jargulinska, Edyta; Jauk, Barbara; Jesenak, Milos; Jilka, Katharina; Jolles, Stephen; Jones, Alison; Jones, Regina; Jonkman-Berk, Birgit; Jönsson, Göran; Joyce, Hilary J.; Juliana, Pricillia; Kabesch, Michael; Kager, Leo; Kahlert, Christian; Kaiser-Labusch, Petra; Kakkas, Ioannis; Kamitz, Dirk; Kanariou, Maria; Kanz, Lothar; Karakoc-Aydiner, Elif; Karanovic, Boris; Kartal-Kaess, Mutlu; Käser, Elisabeth; Katzenstein, Terese L.; Kayserova, Hana; Kelleher, Peter; Kerre, Tessa; Kilic, Sara Sebnem; Kirchner, Martina; Kiwit, Simone; Kiykim, Ayca; Klasen, Jessica; Klaudel-Dreszler, Maja; Klein, Ariane; Klein, Christoph; Klein-Franke, Andreas; Kleine, Ilona; Kleinert, Stefan; Klemann, Christian; Klima, Marion; Kobbe, Robin; Kocacik Uygun, Dilara Fatma; Koch, Melanie; Kochler, Yvonne; Kohistani, Naschla; Kojic, Marina; Kolios, Antonio; Kölsch, Uwe; Koltan, Sylwia; Kondratenko, Irina; Königs, Christoph; Konoplyannikova, Julia; Kopac, Peter; Kopp, Jana; Körholz, Dieter; Körholz, Julia; Korte, Pauline; Kostyuchenko, Larysa; Kötter, Ina; Kracker, Sven; Králícková, Pavlina; Kramm, Christof; Kramme, Philipp;Krausz, Máté; Kreuz, Wolfhart; Kriván, Gergely; Kropshofer, Gabriele; Krüger, Renate; Krystufkova, Olga; Ktistaki, Maria; Kühl, Jörn-Sven; Kühn, Alexander; Kuijpers, Taco W.; Kuis, Wietse; Kullmann, Silke; Kulozik, Andreas; Kumararatne, Dinakantha; Kümmler, Ria; Kündgen, Andrea; Kurenko – Deptuch, Magdalena; Kuss Paula, Cosima; Kütükcüler, Necil; Lafoix-Mignot, Cécile; Lamers, Beate; Lanbeck, Peter; Landais, Paul; Landwehr-Kenzel, Sybille; Langemeyer, Vanessa; Langer, Thorsten; Lankisch, Petra; Lanz, Nadia; Lara, Manrique de; Lara-Villacanas, Eusebia; Laubenthal, Lisa; Laws, Hans-Jürgen; Le Mignot, Loic; Leahy, Ronan; Lee, Jae-Yun; Lehmann, Andrea; Lehmberg, Kai; Lehner, Patricia; Leibfrit, Hans; Leistner, Leoni; Lesch, Petra; Leutner, Simon; Liatsis, Manolis; Libai Véghová, Linda; Liebel, Johanna; Liese, Johannes G.; Linauskiene, Kotryna; Linde, Richard; Linßner, Martina; Lippert, Conrad Ferdinand; Litzman, Jiri; Llobet, Pilar; Lo, Babacar; Lodin, Tariq; Lokaj, Jindrich; Longhino, David; Longhurst, Hilary; Lopes da Silva, Susana; Lorenzen, Catharina; Lougaris, Vassilios; Löw, Doris; Lubatschofski, Annelie; Lucas, Mary; Lutz-Wiegers, Verena; Maaß, Sabine; Maccari, Maria Elena; Macura-Biegun, Anna; Maerz, Vanessa; Maggina, Paraskevi; Mahrenholz, Hannah; Maier, Sarah; Malfroot, Anne; Malinauskiene, Laura; Mannhardt-Laakmann, Wilma; Manson, Ania; Mantkowski, Felicia; Manzey, Petra; Marasco, Carolina; Marcus-Mandelblit, Nufar; Marg, Wolfgang; Markelj, Gasper; Marodi, Laszlo; Marques, José Goncalo; Marques, Laura; Marschall, Karin; Martínez, Natalia; Martinez de la Ossa Saenz-Lopez, Rafael; Martinez-Saguer, Inmaculada; Martire, Baldassarre; Marzollo, Antonio; Masekela, Refiloe; Masjosthusmann, Katja; Masmas, Tania Nicole; Matamoros, Nuria; Mattern, Jutta; Mau-Asam, Pearl; McDermott, Elizabeth; McIntosh, Nichole; Meglic, Karmen Mesko; Meijer, Ruben; Meinhardt, Andrea; Meshaal, Safa; Messaoud, Yasmina; Meyer, Björn; Meyer-Olson, Dirk; Micol, Romain; Micoloc, Bozena; Mielke, Gudrun; Milito, Cinzia; Misbah, Siraj; Mohr, Michael; Mohrmann, Karina; Moin, Mostafa; Molinos, Luis; Möller, Jana; Möller-Nehring, Sarah; Morbach, Henner; Moschese, Viviana; Moser, Olga; Moshous, Despina; Motkowski, Radoslaw;

Motwani, Jayashree; Mouftah Galal, Nermeen; Müglich, Carmen; Mukhina, Anna; Muller, Eva; Müller, Christiane; Müller, Gabriele; Müller, Hedi; Müller, Ingo; Müller, Thomas; Müller, Zoe; Müller-Ladner, Ulf; Müller-Stöver, Sarah; Münstermann, Esther; Murtra Garrell, Núria; Muschaweck, Moritz; Mutert, Miriam; Nademi, Zohreh; Naik, Paru; Näke, Andrea; Nalda, Andrea Martin; Nasrullayeva, Gulnara; Naumann-Bartsch, Nora; Nemitz, Verena;Neth, Olaf; Neubauer, Andreas; Neubert, Jennifer; Neumann, Carla; Niehues, Tim; Niemuth, Mara; Nieuwhof, Chris; Nolkemper, Daniela; Noorani, Sadia; Noorlander, Budde Adya; Notheis, Gundula; Nowatsh, Sanam Amelie; Obenga, Gaelle; Ocak, Suheyla; Oker, Mehmet; Olbrich, Peter; Olipra, Anna; Omran, Heymut; Oommen, Prasad; Orosova, Jaroslava; Oskarsdottir, Solveig; Özsahin, Hülya; Pac, Malgorzata; Pachlopnik Schmid, Jana; Pandolfi, Franco; Papadopoulou-Alataki, Efimia; Papatriantafillou-Schmieder, Anna; Parra-Martinez, Alba; Paschenko, Olga; Pašić, Srdjan; Pasnik, Jarek; Patel, Smita; Pavlík, Martin; Paz Artal, Estela; Peeters, Anouk; Pereira da Silva, Sara Branco; Perez-Becker, Ruy; Perlhagen, Markus; Peter, Hans-Hartmut; Pfreundschuh, Michael; Philippet, Pierre; Picard, Capucine; Pietrucha, Barbara; Pietzsch, Leonora; Piquer Gibert, Monica; Pirolt, Kerstin; Plebani, Alessandro; Pleguezuelo, Daniel E.; Pollok, Katrin; Pommerening, Helena; Popihn, Daniela; Poplonek, Aleksandra; Popp, Marina; Porta, Fulvio; Portegys, Jan; Posfay-Barbe, Klara; Potjewijd, Judith; Poulheim, Sebastian; Prader, Seraina; Prämassing-Scherzer, Petra; Prelog, Martina; Prevot, Johan; Price, Arthur; Price, Timothy; Proesmans, Marijke; Provot, Johan; Quinti, Isabella; Raab, Anna; Rack, Anita; Raffac, Stefan; Ramos Oviedo, Eduardo; Randrianomenjanahary, Philippe; Ranohavimparany, Anja; Raptaki, Maria; Rashidzadeh, Roonaka; Rathwallner, Margit; Reda, Shereen; Redouane, Nahida; Regateiro, Frederico S.; Reichenbach, Janine; Reimers, Bianca; Reinhardt, Cornelia; Reinhardt, Dirk; Reinprecht, Anne; Reiß, Tamara; Reisli, Ismail; Renner, Eleonore; Rezaei, Nima; Richter, Alex; Richter, Darko; Rieber, Nikolaus Peter; Rieckehr, Nadja; Riedel, Marion; Riescher, Heidi; Rischewski, Johannes; Ristl, Nicole; Ritterbusch, Henrike; Ritz, Tanja; Rivier, Francois; Rockstroh, Jürgen K.; Roesler, Joachim; Rofiah, Himatur; Rogerson, Elizabeth; Rolfes, Elisabeth; Roller, Beate; Romanyshyn, Yaryna; Rondelli, Roberto; Roosens, Fien; Rösen-Wolff, Angela; Rösler, Valentina; Roth, Johannes; Rothoeft, Tobias; Roubertie, Agathe; Rübsam, Gesa; Rutgers, Abraham; Ryan, Paul; Sach, Gudrun; Sadeghi, Kambis; Sahrbacher, Ulrike; Saidi, Angelika; Sanal Tezcan, Özden; Sanchez-Ramon, Silvia; Santos, Juan Luis; Sargur, Ravishankar; Savchak, Ihor; Savic, Sinisa; Schaaf, Bernhard; Schaefer, Marzena; Schäfe, Christina; Scharbatke, Eva; Schatorje, Ellen; Schauer, Uwe; Scheibenbogen, Carmen; Scheible, Raphael; Scheinecker, Clemens; Schiller, Romana; Schilling, Beatrice; Schilling, Freimut; Schlieben, Steffi; Schmalbach, Thilo; Schmalzing, Marc Thomas; Schmid, Pirmin; Schmidt, Nadine; Schmidt, Reinhold Ernst; Schmitz, Monika; Schneider, Dominik; Schneider, Dominik T.; Schneppenheim, Reinhard; Scholtes, Cathy; Schölvinck, E.H.; Schönberger, Stefan; Schreiber, Stefan; Schrijvers, Rik; Schroll, Andrea; Schruhl, Simone; Schrum, Johanna; Schubert, Ralf; Schuh, Sebastian; Schulz, Ansgar; Schulz, Claudia; Schulze, Ilka; Schulze-Koops, Hendrik; Schulze-Sturm, Ulf; Schumacher, Eva-Maria; Schürmann, Elvira; Schürmann, Gesine; Schuster, Volker; Schwaneck, Eva; Schwarz, Klaus; Schwarz, Tobias; Schwarze-Zander, Carolynne; Schweigerer, Lothar; Schwinger, Wolfgang; Sediva, Anna; Seebach, Jörg; Seger, Reinhard; Segerer, Florian; Selle, Barbara; Seneviratne, Suranjith; Shabanaj, Hatidje; Shcherbina, Anna; Siepelmeyer, Anne; Siepermann, Kathrin; Simon, Anna; Simon, Arne; Simon-Klingenstein, Katja; Simonovic, Marija; Simsen-Baratault, Merlin;Sindram, Elena; Skapenko, Alla; Skarke, Maiken; Skomska-Pawliszak, Malgorzata; Slatter, Mary; Smet, Julie; Sobh, Ali; Sobik, Bettina; Sogkas, Georgios; Sohm, Michael; Solanich-Moreno, Xavier; Soler Palacín, Pere; Sollinger, Franz; Somech, Raz; Sonnenschein, Anja; Soresina, Annarosa; Sornsakrin, Marijke; Soura, Stavrieta; Spaccarotella, Sabrina; Spadaro, Guiseppe; Sparber-Sauer, Monika; Specker, Christof; Speckmann, Carsten; Speidel, Lisa; Speletas, Matthaios; Stachel, Klaus-Daniel; Stadon, Catherine; Stanislas, Aurélie; Stapornwongkul, Cynthia; Staus, Paulina; Steck, Regina; Steele, Cathal; Steffin, Herbert; Steiner, Urs; Steinmann, Sandra; Stevens, Wim; Stiefel, Martina; Stieger, Sarah; Stiehler, Sophie; Stimm, Hermann; Stojanov, Silvia; Stoll, Matthias; Stoppa-Lyonnet, Dominique; Strapatsas, Tobias; Strauß, Gabriele; Streiter, Monika; Strik-Albers, Riet; Strotmann, Gaby; Suárez Casado, Héctor; Subiza, Jose Luis; Sundin, Mikael; Süß, Birgit; Sutter, Fabienne; Szaflarska, Anna; Szemkus, Monika; Tamary, Hannah; Tantou, Sofia; Tarzi, Michael D.; Taschner, Helga; Tedgard, Ulf; Teixeira, Carla; ten Berge, RJM; Tenbrock, Klaus; Tester, Sabine; Tezcan, Ilhan; Thalguter, Sonja; Thalhammer, Julian; Thoma, Katharina; Thomas, Moira; Thomczyk, Fabian; Thon, Vojtech; Thrasher,

Adrian; Tierney, Patricia; Tietsch, Nadine; Tommasini, Alberto; Tönnes, Beate; Tony, Hans-Peter; Trachana, Maria; Trapp, Carmen; Tricas, Lourdes; Trindade Neves, Maria Conceicao; Trischler, Jordis; Ubieto, Hugo; Uelzen, Anett; Uhlmann, Annette; Ullrich, Jan; Ullrich, Kurt; Ünal, Ekrem; Urbanski, Gerhard; Urschel, Simon; Uszynska, Aleksandra; Vacca, Angelo; Vaganov, N.N.; Vagedes, Daniel; Valicevic, Stefanie; Vallelian, Florence; van Beem, Rachel T; van Damme, Charlotte; van de Ven, Annick; van den Berg, J. Merlijn; van der Flier, Michiel; van Dissel, J.T.; van Hagen, P.M.; van Montfrans, J.M.; van Ogtrop, Geoffrey; van Rens, Jacqui; van Riel, Christel A.M.P.; van Royen-Kerkhof, Annet; van Well, G.Th.J.; Vasiliki, Antari; Velbri, Sirje; Vencken, Jo; Ventura, Alessandro; Vermeulen, François; Vermylen, Christiane; Viemann, Dorothee; Viereck, Anja; Villa, Anna; Vincke, Jeroen; Vinnemeier-Laubenthal, Lisa; Vo Thi, Kim Duy; Vollbach, Kristina; Volokha, Alla; von Bernuth, Horst; von Bismarck, Philipp; Voss, Rebecca; Voß, Sandra; Vural, Yüksel; Wachuga, Heike; Wagner, Norbert; Wagström, Per; Wahle, Matthias; Wahn, Volker; Wapp, Nadine; Warnatz, Klaus; Warneke, Monika; Warris, Adilia; Wasmuth, Jan-Christian; Wasserfallen, Jean-Blaise; Wawer, Angela; Weber, Manfred; Weemaes, Corrie MR;Wehrle, Julius; Weidinger, Stephan; Weiß, Michael; Weißbarth-Riedel, Elisabeth; Werner, Antje; Wessel, Sara; Westkemper, Marco; Wicher, Monika; Wickmann, Lutz; Wiegert, Sabine; Wiehe, Monique; Wiehler, Katharina; Wiesböck, Lydia; Wiesik-Szewczyk, Ewa; Williams, Anthony; Winkler, Beate; Winkler, Christel; Winkler, Martina; Winkler, Melanie; Wintergerst, Uwe; Wisgrill, Lukas; Witte, Torsten; Wittkowski, Helmut; Wolf, Barbara; Wölke, Sandra; Wolschner, Christina; Wolska-Kusnierz, Beata; Wood, Philip; Workman, Sarita; Worth, Austen; Wortmann, Michaela; Wuillemin, Walter Alfred; Wulffraat, Nico M; Wustrau, Katharina; Wyndham-Thomas, Chloé; Yegin, Olcay; Yildiran, Alisan; Yilmaz, Denise; Young, Patrick; Yucel, Esra; Zečević, Milica; Zepp, Fred; Zetzsche, Klaus; Zeuner, Rainald; Zielen, Stefan; Zimmermann, Martina; Želimir, Erić; Abou-Chahla, Wadih; Aladjidi, Nathalie; Armari-Alla, Corinne; Barlogis, Vincent; Bayart, Sophie; Blanche, Stéphane; Bodet, Damien; Bonnotte, Bernard; Borie, Raphaël; Boutard, Patrick; Boutboul, David; Briandet, Claire; Brion, Jean-Paul; Brouard, Jacques; Castelle, Martin; Cathebras, Pascal; Carausu, Liana; Catherinot, Emilie; Cheikh, Nathalie; Cheminant, Morgane; Comont, Thibault; Couderc, Louis-Jean; Cougoul, Pierre; Deville, Anne; Devoldere, Catherine; Dore, Eric; Dulieu, Fabienne; Durieu, Isabelle; Entz-Werle, Natacha; Fieschi, Claire; Galicier, Lionel; Gandemer, Virginie; Gardembas, Martine; Gourguechon, Clément; Grosbois, Bernard; Guffroy, Aurélien; Guitton, Corinne; Guillerm, Gaëlle; Hamidou, Mohamed; Haro, Sophie; Hatchuel, Yves; Hermine, Olivier; Hoarau, Cyrille; Humbert, Sébastien; Jaccard, Arnaud; Jais, Jean-Philippe; Jannier, Sarah; Jacquot, Serge; Jaussaud, Roland; Jeandel, Pierre-Yves; Jeziorski, Eric; Kebaïli, Kamila; Korganow, Anne-Sophie; Lambotte, Olivier; Lanternier, Fanny; Larroche, Claire; Launay, David; Le Guenno, Guillaume; Le Moigne, Emmanuelle; Lecuit, Marc; Lefèvre, Guillaume; Lelièvre, Jean-Daniel; Levy, Romain; Li-Thiao-Te, Valérie; Lortholary, Olivier; Luca, Luminita; Mallebranche, Coralie; Malphettes, Marion; Marie-Cardine, Aude; Martin-Silva, Nicolas; Masseau, Agathe; Merlin, Etienne; Millot, Frédéric; Miot, Charline; Mirgot, Floriane; Moussouni, Nabila; Mouthon, Luc; Néel, Antoine; Neven, Bénédicte; Nouar, Dalila; Nove-Josserand, Raphaële; Ouachée-Chardin, Marie; Pagnier, Anne; Paillard, Catherine; Pasquet, Marlène; Pellier, Isabelle; Perlat, Antoinette; Piguet, Christophe; Plantaz, Dominique; Rivière, Sophie; Raffray, Loïc; Roblot, Pascal; Rohrlich, Pierre-Simon; Royer, Bruno; Salle, Valéry; Salvator, Hélène; Sarrot-Reynauld, Françoise; Servettaz, Amélie; Stephan, Jean-Louis; Schleinitz, Nicolas; Suarez, Felipe; Swiader, Laure; Taque, Sophie; Thomas, Caroline; Tournilhac, Olivier; Thumerelle, Caroline; Vannier, Jean-Pierre; Viallard, Jean-François.

619 # References


620 1. Gray PE, David C. Inborn Errors of Immunity and Autoimmune Disease. *J Allergy Clin*
621 *Immunol Pract* 2023;**11**(6):1602-22 doi: 10.1016/j.jaip.2023.04.018.

622 2. Hagele P, Staus P, Scheible R, Uhlmann A, Heeg M, Klemann C, Maccari ME,
623 Ritterbusch H, Armstrong M, Cutcutache I, Elliott KS, von Bernuth H, Leahy TR, Leyh
624 J, Holzinger D, Lehmberg K, Svec P, Masjosthusmann K, Hambleton S, Jakob M,
625 Sparber-Sauer M, Kager L, Puzik A, Wolkewitz M, Lorenz MR, Schwarz K,
626 Speckmann C, Rensing-Ehl A, Ehl S, group As. Diagnostic evaluation of paediatric
627 autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort
628 study. *Lancet Haematol* 2024;**11**(2):e114-e26 doi: 10.1016/S2352-3026(23)00362-9.

629 3. Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies in
630 patients with primary immunodeficiency disorders. *The Journal of allergy and clinical*
631 *immunology* 2018;**141**(1):59-68 e4 doi: 10.1016/j.jaci.2017.06.009.

632 4. Seidel MG, Hauck F. Multilayer concept of autoimmune mechanisms and manifestations
633 in inborn errors of immunity: Relevance for precision therapy. *The Journal of allergy*
634 *and clinical immunology* 2024;**153**(3):615-28 e4 doi: 10.1016/j.jaci.2023.12.022.

635 5. Vaseghi-Shanjani M, Smith KL, Sara RJ, Modi BP, Branch A, Sharma M, Lu HY, James
636 EL, Hildebrand KJ, Biggs CM, Turvey SE. Inborn errors of immunity manifesting as
637 atopic disorders. *The Journal of allergy and clinical immunology* 2021;**148**(5):1130-39
638 doi: 10.1016/j.jaci.2021.08.008.

639 6. Poli MC, Aksentijevich I, Bousfiha A, Cunningham-Rundles C, Hambleton S, Klein C,
640 Morio T, Picard C, Puel A, Rezaei N, Seppänen MRJ, Somech R, Su HC, Sullivan
641 KE, Torgerson TR, Meyts I, Tangye SG. Human inborn errors of immunity: 2024
642 Update on the classification from the International Union of Immunological Societies
643 Expert Committee. Secondary Human inborn errors of immunity: 2024 Update on the
644 classification from the International Union of Immunological Societies Expert
645 Committee 2024. https://wp-iuis.s3.eu-west-
646 1.amazonaws.com/app/uploads/2025/01/08170257/IEI-Final-Update-of-2024-Report-
647 Jan-2025.pdf.

648 7. Seidel MG. Rethinking PIDs: Why the distinction between primary and secondary immune
649 disorders is more frequently relevant than that between inborn and acquired errors of
650 immunity. *The Journal of allergy and clinical immunology* 2024;**153**(6):1543-45 doi:
651 10.1016/j.jaci.2024.01.018.

652 8. Grimbacher B, Party ERW. The European Society for Immunodeficiencies (ESID) registry
653 2014. *Clinical and experimental immunology* 2014;**178 Suppl 1**(Suppl 1):18-20 doi:
654 10.1111/cei.12496.

655 9. Guzman D, Veit D, Knerr V, Kindle G, Gathmann B, Eades-Perner AM, Grimbacher B.
656 The ESID Online Database network. *Bioinformatics* 2007;**23**(5):654-5 doi:
657 10.1093/bioinformatics/btl675.

658 10. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, Scheible R,
659 Rusch S, Gasteiger LM, Grimbacher B, Mahlaoui N, Ehl S, Party ERW, collaborators.
660 The European Society for Immunodeficiencies (ESID) Registry Working Definitions
661 for the Clinical Diagnosis of Inborn Errors of Immunity. *J Allergy Clin Immunol Pract*
662 2019;**7**(6):1763-70 doi: 10.1016/j.jaip.2019.02.004.

663 11. Alligon M, Mahlaoui N, Bouaziz O. Pitfalls in time-to-event analysis of registry data: a
664 tutorial based on simulated and real cases. *Front Epidemiol* 2024;**4**:1386922 doi:
665 10.3389/fepid.2024.1386922.

666 12. Thalhammer J, Kindle G, Nieters A, Rusch S, Seppanen MRJ, Fischer A, Grimbacher B,
667 Edgar D, Buckland M, Mahlaoui N, Ehl S, European Society for Immunodeficiencies
668 Registry Working P. Initial presenting manifestations in 16,486 patients with inborn
669 errors of immunity include infections and noninfectious manifestations. *The Journal of*
670 *allergy and clinical immunology* 2021;**148**(5):1332-41 e5 doi:
671 10.1016/j.jaci.2021.04.015.

672 13. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, Sohani M,
673 Shirmast P, Chavoshzadeh Z, Mahdaviani SA, Kalantari A, Tavakol M, Jabbari-Azad
674 F, Ahanchian H, Momen T, Sherkat R, Sadeghi-Shabestari M, Aleyasin S,
675 Esmaeilzadeh H, Al-Herz W, Bousfiha AA, Condino-Neto A, Seppanen M, Sullivan
676 KE, Hammarstrom L, Modell V, Modell F, Quinn J, Orange JS, Aghamohammadi A.
677 Global systematic review of primary immunodeficiency registries. *Expert Rev Clin*
678 *Immunol* 2020;**16**(7):717-32 doi: 10.1080/1744666X.2020.1801422.

679 14. European Society for Immunodeficiencies Registry WP. ESID-R Publications. Secondary
680 ESID-R Publications 2025. https://esid.org/working-parties/registry-working-
681 party/registry-publications/.

682 15. Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG, Veys P, Gennery AR,
683 Gaspar HB. Neonatal diagnosis of severe combined immunodeficiency leads to
684 significantly improved survival outcome: the case for newborn screening. *Blood*
685 2011;**117**(11):3243-6 doi: 10.1182/blood-2010-08-300384.

686 16. Chan K, Puck JM. Development of population-based newborn screening for severe
687 combined immunodeficiency. *The Journal of allergy and clinical immunology*
688 2005;**115**(2):391-8 doi: 10.1016/j.jaci.2004.10.012.

689 17. Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker
690 MW. Statewide newborn screening for severe T-cell lymphopenia. *JAMA*
691 2009;**302**(22):2465-70 doi: 10.1001/jama.2009.1806.

692 18. Thakar MS, Logan BR, Puck JM, Dunn EA, Buckley RH, Cowan MJ, O'Reilly RJ, Kapoor
693 N, Satter LF, Pai SY, Heimall J, Chandra S, Ebens CL, Chellapandian D, Williams O,
694 Burroughs LM, Saldana BD, Rayes A, Madden LM, Chandrakasan S, Bednarski JJ,
695 2nd, DeSantes KB, Cuvelier GDE, Teira P, Gillio AP, Eissa H, Knutsen AP, Goldman
696 FD, Aquino VM, Shereck EB, Moore TB, Caywood EH, Lugt MTV, Rozmus J, Broglie
697 L, Yu LC, Shah AJ, Andolina JR, Liu X, Parrott RE, Dara J, Prockop S, Martinez CA,
698 Kapadia M, Jyonouchi SC, Sullivan KE, Bleesing JJ, Chaudhury S, Petrovic A, Keller
699 MD, Quigg TC, Parikh S, Shenoy S, Seroogy C, Rubin T, Decaluwe H, Routes JM,
700 Torgerson TR, Leiding JW, Pulsipher MA, Kohn DB, Griffith LM, Haddad E, Dvorak
701 CC, Notarangelo LD. Measuring the effect of newborn screening on survival after
702 haematopoietic cell transplantation for severe combined immunodeficiency: a 36-
703 year longitudinal study from the Primary Immune Deficiency Treatment Consortium.
704 *Lancet* 2023;**402**(10396):129-40 doi: 10.1016/S0140-6736(23)00731-6.

705 19. I. Jspeert H, Edwards ESJ, O'Hehir RE, Dalm V, van Zelm MC. Update on inborn errors
706 of immunity. *The Journal of allergy and clinical immunology* 2024 doi:
707 10.1016/j.jaci.2024.12.1075.

20. Seidel MG. Baby genome screening: paving the way to genetic discrimination? *Bmj* 2017;**358**:j3294 doi: 10.1136/bmj.j3294.

21. Mahlaoui N, Jais JP, Brosselin P, Mignot C, Beaurain B, Brito C, Costes L, Courteille V, De Vergnes N, Alcais A, Fischer A, Collaborators CPS. Prevalence of primary immunodeficiencies in France is underestimated. *The Journal of allergy and clinical immunology* 2017;**140**(6):1731-33 doi: 10.1016/j.jaci.2017.06.020.

22. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. *Nature* 1993;**361**(6409):226-33 doi: 10.1038/361226a0.

23. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. *Science* 2014;**345**(6204):1623-27 doi: 10.1126/science.1255904.

24. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schaffer AA, Gruning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LSK, Sansom DM, Grimbacher B. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nat Med* 2014;**20**(12):1410-16 doi: 10.1038/nm.3746.

25. Fliegauf M, Bryant VL, Frede N, Slade C, Woon ST, Lehnert K, Winzer S, Bulashevska A, Scerri T, Leung E, Jordan A, Keller B, de Vries E, Cao H, Yang F, Schaffer AA, Warnatz K, Browett P, Douglass J, Ameratunga RV, van der Meer JW, Grimbacher B. Haploinsufficiency of the NF-kappaB1 Subunit p50 in Common Variable Immunodeficiency. *Am J Hum Genet* 2015;**97**(3):389-403 doi: 10.1016/j.ajhg.2015.07.008.

26. Nieto-Patlan A, Ross J, Mohan S, Paczosa MK, Soliman R, Sarmento O, Aliu E, Thiyagarajan L, Chandra A, Picard C, Warnatz K, Jolles S, Lesmana H, Maglione PJ, Platt CD, Sediva A, Sullivan KE, Zhang K, Raval F, Tangye SG, Abraham RS. Curation of gene-disease relationships in primary antibody deficiencies using the ClinGen validation framework. *The Journal of allergy and clinical immunology* 2025 doi: 10.1016/j.jaci.2025.01.005.

27. Haimel M, Pazmandi J, Heredia RJ, Dmytrus J, Bal SK, Zoghi S, van Daele P, Briggs TA, Wouters C, Bader-Meunier B, Aeschlimann FA, Caorsi R, Eleftheriou D, Hoppenreijs E, Salzer E, Bakhtiar S, Derfalvi B, Saettini F, Kusters MAA, Elfeky R, Truck J, Riviere JG, van der Burg M, Gattorno M, Seidel MG, Burns S, Warnatz K, Hauck F, Brogan P, Gilmour KC, Schuetz C, Simon A, Bock C, Hambleton S, de Vries E, Robinson P, van Gijn M, Boztug K. Curation and Expansion of Human Phenotype Ontology for Defined Groups of Inborn Errors of Immunity. *The Journal of allergy and clinical immunology* 2021 doi: 10.1016/j.jaci.2021.04.033.

753 28. Akalu YT, Bogunovic D. Inborn errors of immunity: an expanding universe of disease and
754 genetic architecture. *Nat Rev Genet* 2024;**25**(3):184-95 doi: 10.1038/s41576-023-
755 00656-z.

756 29. Passweg JR, Baldomero H, Ciceri F, de la Camara R, Glass B, Greco R, Hazenberg
757 MD, Kalwak K, McLornan DP, Neven B, Peric Z, Risitano AM, Ruggeri A, Snowden
758 JA, Sureda A. Hematopoietic cell transplantation and cellular therapies in Europe
759 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from
760 the EBMT. *Bone marrow transplantation* 2024;**59**(6):803-12 doi: 10.1038/s41409-
761 024-02248-9.

762 30. European Commission E-E. SPIDER pseudonymisation tool. Secondary SPIDER
763 pseudonymisation tool 2024. https://eu-rd-platform.jrc.ec.europa.eu/spider/.

764 31. Riviere JG, Soler Palacin P, Butte MJ. Proceedings from the inaugural Artificial
765 Intelligence in Primary Immune Deficiencies (AIPID) conference. *The Journal of*
766 *allergy and clinical immunology* 2024;**153**(3):637-42 doi: 10.1016/j.jaci.2024.01.002.

767 32. Kohler S, Gargano M, Matentzoglu N, Carmody LC, Lewis-Smith D, Vasilevsky NA,
768 Danis D, Balagura G, Baynam G, Brower AM, Callahan TJ, Chute CG, Est JL, Galer
769 PD, Ganesan S, Griese M, Haimel M, Pazmandi J, Hanauer M, Harris NL, Hartnett
770 MJ, Hastreiter M, Hauck F, He Y, Jeske T, Kearney H, Kindle G, Klein C, Knoflach K,
771 Krause R, Lagorce D, McMurry JA, Miller JA, Munoz-Torres MC, Peters RL, Rapp
772 CK, Rath AM, Rind SA, Rosenberg AZ, Segal MM, Seidel MG, Smedley D, Talmy T,
773 Thomas Y, Wiafe SA, Xian J, Yuksel Z, Helbig I, Mungall CJ, Haendel MA, Robinson
774 PN. The Human Phenotype Ontology in 2021. *Nucleic Acids Res*
775 2021;**49**(D1):D1207-D17 doi: 10.1093/nar/gkaa1043.

776

# Legends

**Table 1. *European Society for Immunodeficiencies* (ESID) registry patient characteristics.**

**Figure 1. Ages and main manifestations at onset of inborn errors of immunity (IEI)** or primary immune disorders (PID)**. *A,*** age groups of age at disease onset, clinical diagnosis of IEI/PID, and of genetic diagnosis are shown. ***B,*** Venn diagram of main manifestations of IEI/PID with absolute patient numbers and proportions.

**Figure 2. Representation of genetic diagnoses of known IEI/PID in the ESID registry. *A,*** the number and proportion of patients with a genetic versus those without a genetic diagnosis is shown in descending order. ***B,*** the top 5 genetic defects or deletions registered in the ESIDR per all 10 IUIS categories of IEI are presented; the nomenclature in registry diagnosis and gene fields was not regularly updated/changed, showing, *e.g.*, GP91-phox instead of *CYBB* and p47-phox instead of *NCF1*.

**Figure 3. Major treatment modalities of patients with IEI/PID as recorded in the ESID-R.** Relative proportions of major treatments such as immunoglobulin replacement therapy (data on route, interval and dose were recorded but are not shown), allogeneic hematopoietic stem cell transplantation (AlloSCT), autologous gene therapy (GT) and on splenectomy. Only a proportion of centers recorded data on immune modifying treatment (not shown), and the ESID-R does not capture data on antimicrobial therapy. “Unknown/not listed” and IgRT refer to the latest follow-up time point.

**Figure 4. Survival probabilities of main categories of IEI/PID and the living status at last news. *A,*** Inverse cumulative incidence curves as described and referenced in the supplementary material. Start = age at diagnosis, stop = age at last news, event = living status (0= censored, 1 = deceased first, 2 = curative therapy first). There were 21,206 patients censored, 1,960 patients who deceased first, and 2,901 patients who had a curative therapy first (not showing deaths after curative therapy); roman numbers refer to the IUIS categories for IEI/PID as listed in Figure 2B.

**Figure 5. Number, categories and citation counts of ESID-R-based publications.** A total of 7,980 citations of 84 peer-reviewed ESID-R-based publications until early 2024 was recorded. See also the website for regular updates of ESID-R-related publications at https://esid.org/working-parties/registry-working-party/registry-publications/

807 Table 1. *European Society for Immunodeficiencies* (ESID) registry patient characteristics.

| Covariate | Values | Whole cohort | CID (I) | Syndromic (II) | PAD (III) | PIRD (IV) | Phagocyte (V) | Innate (VI) | AIS (VII) | Complement (VIII) | BMF (IX) | Phenocopies (X) | other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | N=30628 | N=2531 | N=4239 | N=15123 | N=2171 | N=2548 | N=823 | N=1042 | N=1482 | N=85 | N=30 | N=554 |
| Gender (male) | M | 16767 (54.8%) | 1470 (58.1%) | 2473 (58.3%) | 7782 (51.5%) | 1329 (61.2%) | 1693 (66.5%) | 387 (47%) | 575 (55.2%) | 681 (46%) | 57 (67.1%) | 19 (63.3%) | 301 (54.3%) |
| | F | 13855 (45.2%) | 1061 (41.9%) | 1766 (41.7%) | 7337 (48.5%) | 841 (38.8%) | 854 (33.5%) | 436 (53%) | 467 (44.8%) | 801 (54%) | 28 (32.9%) | 11 (36.7%) | 253 (45.7%) |
| Year of birth | | 1997 [1976;2008] | 2007 [1997;2014] | 2005 [1995;2012] | 1984 [1963;2001] | 2004 [1993;2011] | 2002 [1991;2010] | 2003 [1991;2011] | 2008 [1999;2013] | 1991 [1972;2006] | 2004 [1987;2011] | 2001.5 [1995;2008.5] | 1998 [1974;2007] |
| Familial case | N | 21854 (76.6%) | 1725 (72.9%) | 3002 (74.1%) | 11949 (85.4%) | 1266 (61.1%) | 1468 (65.4%) | 492 (62.2%) | 771 (76.6%) | 645 (46.5%) | 57 (75%) | 28 (93.3%) | 451 (87.7%) |
| | Y | 6681 (23.4%) | 641 (27.1%) | 1047 (25.9%) | 2049 (14.6%) | 805 (38.9%) | 778 (34.6%) | 299 (37.8%) | 236 (23.4%) | 742 (53.5%) | 19 (25%) | 2 (6.7%) | 63 (12.3%) |
| Consanguinity | N | 24731 (87.2%) | 1426 (60.8%) | 3247 (82.1%) | 13381 (95.5%) | 1602 (78.8%) | 1699 (75.6%) | 589 (77.3%) | 920 (93.2%) | 1303 (93.1%) | 66 (84.6%) | 28 (100%) | 470 (92.7%) |
| | Y | 3624 (12.8%) | 921 (39.2%) | 708 (17.9%) | 631 (4.5%) | 432 (21.2%) | 547 (24.4%) | 173 (22.7%) | 67 (6.8%) | 96 (6.9%) | 12 (15.4%) | 0 (0%) | 37 (7.3%) |
| Age at onset of symptoms | | 3 [0.4;14.1] | 0.3 [0;1.6] | 0.5 [0;2.2] | 8 [2;30] | 2.2 [0.3;7.5] | 0.7 [0.1;3] | 1.2 [0.2;3.8] | 2.8 [0.7;5] | 8 [3;18] | 3 [0.3;8.1] | 2.8 [0.6;4.9] | 3 [0.7;15.4] |
| Immune dysregulation at onset | N | 21482 (77.2%) | 1712 (77.5%) | 3242 (84.1%) | 11175 (80.3%) | 616 (31.6%) | 1944 (86.2%) | 632 (84.9%) | 536 (55%) | 1182 (88.3%) | 49 (67.1%) | 4 (13.3%) | 390 (80.7%) |
| | Y | 6347 (22.8%) | 498 (22.5%) | 613 (15.9%) | 2741 (19.7%) | 1335 (68.4%) | 311 (13.8%) | 112 (15.1%) | 438 (45%) | 156 (11.7%) | 24 (32.9%) | 26 (86.7%) | 93 (19.3%) |
| Infection at onset | N | 8133 (28.9%) | 436 (19.6%) | 2195 (56.6%) | 1920 (13.6%) | 1161 (59.6%) | 590 (26%) | 108 (14.4%) | 705 (72.5%) | 827 (61.5%) | 44 (60.3%) | 19 (67.9%) | 128 (26.3%) |
| | Y | 19961 (71.1%) | 1786 (80.4%) | 1680 (43.4%) | 12202 (86.4%) | 787 (40.4%) | 1681 (74%) | 643 (85.6%) | 267 (27.5%) | 518 (38.5%) | 29 (39.7%) | 9 (32.1%) | 359 (73.7%) |
| Malignancy at onset | N | 27294 (98.3%) | 2180 (98.6%) | 3766 (97.8%) | 13620 (98.1%) | 1885 (97.1%) | 2235 (99.4%) | 741 (99.7%) | 969 (99.8%) | 1333 (99.8%) | 69 (94.5%) | 25 (89.3%) | 471 (97.7%) |
| | Y | 479 (1.7%) | 30 (1.4%) | 85 (2.2%) | 269 (1.9%) | 57 (2.9%) | 13 (0.6%) | 2 (0.3%) | 2 (0.2%) | 3 (0.2%) | 4 (5.5%) | 3 (10.7%) | 11 (2.3%) |
| Syndromic manifestations at onset | N | 24549 (88.3%) | 2046 (92.6%) | 1651 (42.7%) | 13574 (97.7%) | 1798 (92.5%) | 2075 (92.3%) | 683 (91.8%) | 919 (94.6%) | 1274 (95.4%) | 40 (54.8%) | 28 (100%) | 461 (95.4%) |
| | Y | 3253 (11.7%) | 164 (7.4%) | 2220 (57.3%) | 320 (2.3%) | 145 (7.5%) | 174 (7.7%) | 61 (8.2%) | 52 (5.4%) | 62 (4.6%) | 33 (45.2%) | 0 (0%) | 22 (4.6%) |
| Other onset | N | 24466 (87.9%) | 1992 (90.1%) | 3298 (85.5%) | 12947 (93.1%) | 1782 (91.6%) | 2086 (92.7%) | 685 (92.1%) | 545 (55.6%) | 647 (48.1%) | 59 (80.8%) | 28 (96.6%) | 397 (81.9%) |
| | Y | 3366 (12.1%) | 220 (9.9%) | 559 (14.5%) | 963 (6.9%) | 163 (8.4%) | 164 (7.3%) | 59 (7.9%) | 436 (44.4%) | 699 (51.9%) | 14 (19.2%) | 1 (3.4%) | 88 (18.1%) |

| Covariate | Values | Whole cohort | CID (I) | Syndromic (II) | PAD (III) | PIRD (IV) | Phagocyte (V) | Innate (VI) | AIS (VII) | Complement (VIII) | BMF (IX) | Phenocopies (X) | other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | N=30628 | N=2531 | N=4239 | N=15123 | N=2171 | N=2548 | N=823 | N=1042 | N=1482 | N=85 | N=30 | N=554 |
| No clinical symptoms | N | 27605 (94.1%) | 2188 (91%) | 3770 (92.5%) | 13875 (95.9%) | 1926 (91.5%) | 2238 (92.3%) | 735 (91.9%) | 966 (97.2%) | 1326 (91.2%) | 71 (91%) | 28 (100%) | 482 (97.6%) |
| | Y | 1725 (5.9%) | 217 (9%) | 306 (7.5%) | 595 (4.1%) | 180 (8.5%) | 187 (7.7%) | 65 (8.1%) | 28 (2.8%) | 128 (8.8%) | 7 (9%) | 0 (0%) | 12 (2.4%) |
| Age at clinical diagnosis (CD) | | 8.2 [2;30.1] | 0.7 [0.3;4.6] | 2.4 [0.4;6.9] | 22 [6.2;44] | 5.1 [1;13] | 2 [0.5;7] | 4.2 [1.1;14] | 5 [2.7;11.4] | 15 [5.2;28.8] | 5 [1.3;13.7] | 5.2 [3;9.8] | 7.5 [2.3;34.1] |
| Delay between onset and CD | | 1.3 [0.1;5.1] | 0.2 [0;1.3] | 0.8 [0;3.9] | 2.7 [0.7;7.5] | 0.4 [0;3.4] | 0.5 [0.1;2.2] | 1 [0.1;5.6] | 1.5 [0.5;4] | 1.1 [0.1;7] | 0.5 [0.1;2.1] | 0.9 [0.3;3.9] | 1.7 [0.3;4.7] |
| Genetics | Mutation found | 12774 (44.5%) | 1470 (63.1%) | 3647 (88.8%) | 2251 (16%) | 1671 (80.8%) | 1693 (71.8%) | 529 (68.1%) | 662 (65.3%) | 772 (55.6%) | 49 (71%) | 30 (100%) | 0 (0%) |
| | No mutation found | 2852 (9.9%) | 319 (13.7%) | 79 (1.9%) | 1850 (13.1%) | 195 (9.4%) | 106 (4.5%) | 81 (10.4%) | 71 (7%) | 27 (1.9%) | 9 (13%) | 0 (0%) | 115 (24.7%) |
| | Not tested | 11956 (41.7%) | 403 (17.3%) | 325 (7.9%) | 9398 (66.8%) | 125 (6%) | 478 (20.3%) | 97 (12.5%) | 250 (24.7%) | 569 (41%) | 8 (11.6%) | 0 (0%) | 303 (65%) |
| | Pending | 1097 (3.8%) | 136 (5.8%) | 57 (1.4%) | 576 (4.1%) | 76 (3.7%) | 80 (3.4%) | 70 (9%) | 31 (3.1%) | 20 (1.4%) | 3 (4.3%) | 0 (0%) | 48 (10.3%) |
| Age at genetic diagnosis (GD) | | 5.5 [1.1;15] | 0.9 [0.3;6.7] | 3.2 [0.4;9.7] | 9.4 [2.9;25] | 8.3 [1.8;17.3] | 4.4 [1.1;12.7] | 10 [3.2;20.4] | 8.4 [4;22] | 13.2 [5;26.9] | 8.2 [3.6;17.4] | 9.8 [5;14.1] | NA [NA;NA] |
| Delay between CD and GD | | 0.3 [0;2.9] | 0.2 [0;1.2] | 0.2 [0;1.7] | 1.3 [0.1;8.8] | 0.2 [0;2.2] | 0.3 [0;2.2] | 0.8 [0.1;5.9] | 0.1 [0;1.1] | 0.2 [0;1.6] | 0.4 [0.1;2.6] | 1 [0.2;4.9] | NA [NA;NA] |
| Reason of GD | Clinical | 8787 (88%) | 975 (87.7%) | 2601 (90.8%) | 1629 (89.2%) | 1192 (82.2%) | 1081 (90.6%) | 380 (85.4%) | 515 (88.6%) | 350 (77.8%) | 39 (92.9%) | 25 (96.2%) | 0 (0%) |
| | Family | 975 (9.8%) | 77 (6.9%) | 153 (5.3%) | 170 (9.3%) | 245 (16.9%) | 100 (8.4%) | 63 (14.2%) | 65 (11.2%) | 99 (22%) | 3 (7.1%) | 0 (0%) | 0 (0%) |
| | Neonatal | 114 (1.1%) | 41 (3.7%) | 45 (1.6%) | 20 (1.1%) | 2 (0.1%) | 3 (0.3%) | 0 (0%) | 1 (0.2%) | 1 (0.2%) | 0 (0%) | 1 (3.8%) | 0 (0%) |
| | Prenatal | 112 (1.1%) | 19 (1.7%) | 64 (2.2%) | 7 (0.4%) | 11 (0.8%) | 9 (0.8%) | 2 (0.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Sequencing method of GD | Gene sequencing | 7693 (83.3%) | 848 (80.1%) | 2122 (82%) | 1421 (83.5%) | 1154 (85.3%) | 970 (87.7%) | 323 (77.5%) | 459 (85.5%) | 347 (84.6%) | 26 (70.3%) | 23 (95.8%) | 0 (0%) |
| | Non-genetic definitive test | 441 (4.8%) | 35 (3.3%) | 284 (11%) | 11 (0.6%) | 12 (0.9%) | 59 (5.3%) | 3 (0.7%) | 0 (0%) | 36 (8.8%) | 1 (2.7%) | 0 (0%) | 0 (0%) |
| | Whole exome/genome sequencing | 1100 (11.9%) | 176 (16.6%) | 183 (7.1%) | 270 (15.9%) | 187 (13.8%) | 77 (7%) | 91 (21.8%) | 78 (14.5%) | 27 (6.6%) | 10 (27%) | 1 (4.2%) | 0 (0%) |
| Malignancy | N | 18176 (91.1%) | 1578 (93.4%) | 2491 (88.9%) | 8759 (89.4%) | 1595 (91.4%) | 1609 (95.6%) | 569 (94.7%) | 604 (98.1%) | 632 (97.7%) | 66 (90.4%) | 16 (72.7%) | 257 (89.9%) |
| | Y | 1783 (8.9%) | 112 (6.6%) | 312 (11.1%) | 1034 (10.6%) | 150 (8.6%) | 74 (4.4%) | 32 (5.3%) | 12 (1.9%) | 15 (2.3%) | 7 (9.6%) | 6 (27.3%) | 29 (10.1%) |

| Covariate | Values | Whole cohort | CID (I) | Syndromic (II) | PAD (III) | PIRD (IV) | Phagocyte (V) | Innate (VI) | AIS (VII) | Complement (VIII) | BMF (IX) | Phenocopies (X) | other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | N=30628 | N=2531 | N=4239 | N=15123 | N=2171 | N=2548 | N=823 | N=1042 | N=1482 | N=85 | N=30 | N=554 |
| Covid19 | N | 5380 (70.3%) | 456 (81%) | 801 (76.1%) | 2613 (64.1%) | 434 (74.2%) | 363 (81%) | 130 (77.4%) | 260 (74.9%) | 177 (76.3%) | 15 (78.9%) | 6 (75%) | 125 (79.6%) |
| | Y | 2273 (29.7%) | 107 (19%) | 251 (23.9%) | 1461 (35.9%) | 151 (25.8%) | 85 (19%) | 38 (22.6%) | 87 (25.1%) | 55 (23.7%) | 4 (21.1%) | 2 (25%) | 32 (20.4%) |
| Living status | Alive | 20680 (67.5%) | 1419 (56.1%) | 2580 (60.9%) | 10740 (71%) | 1519 (70%) | 1534 (60.2%) | 546 (66.3%) | 729 (70%) | 1127 (76%) | 52 (61.2%) | 22 (73.3%) | 412 (74.4%) |
| | Deceased | 3216 (10.5%) | 615 (24.3%) | 676 (15.9%) | 1117 (7.4%) | 356 (16.4%) | 269 (10.6%) | 87 (10.6%) | 23 (2.2%) | 18 (1.2%) | 22 (25.9%) | 3 (10%) | 30 (5.4%) |
| | Lost to follow-up | 6732 (22%) | 497 (19.6%) | 983 (23.2%) | 3266 (21.6%) | 296 (13.6%) | 745 (29.2%) | 190 (23.1%) | 290 (27.8%) | 337 (22.7%) | 11 (12.9%) | 5 (16.7%) | 112 (20.2%) |
| Age at last follow-up/death | | 20.2 [9.4;42.6] | 8.7 [2;18.7] | 12.5 [6.3;19.9] | 35.4 [16.9;55.9] | 14.8 [6.5;24.2] | 13.7 [5.8;23.6] | 15 [7;27.3] | 11.2 [6;20.9] | 27.3 [13.6;46.4] | 14.6 [6.3;23.7] | 18.2 [12;22.8] | 19 [8.4;44.1] |
| Living status (stops at CT) | Alive at last follow-up | 24222 (81.1%) | 928 (37.1%) | 3144 (76.5%) | 13522 (92%) | 1313 (61%) | 1680 (67%) | 695 (86.1%) | 956 (95.1%) | 1463 (99.1%) | 41 (49.4%) | 25 (83.3%) | 455 (90.6%) |
| | Deceased | 2226 (7.5%) | 258 (10.3%) | 496 (12.1%) | 966 (6.6%) | 186 (8.6%) | 181 (7.2%) | 74 (9.2%) | 17 (1.7%) | 11 (0.7%) | 9 (10.8%) | 3 (10%) | 25 (5%) |
| | Curative therapy | 3431 (11.5%) | 1315 (52.6%) | 470 (11.4%) | 216 (1.5%) | 653 (30.3%) | 648 (25.8%) | 38 (4.7%) | 32 (3.2%) | 2 (0.1%) | 33 (39.8%) | 2 (6.7%) | 22 (4.4%) |
| Age at last follow-up (stops at CT) | | 19.4 [8;42.6] | 1.3 [0.5;11] | 11.4 [5.2;19.3] | 35.5 [16.8;55.9] | 12.1 [3.2;22.7] | 11.6 [4;21.8] | 14.6 [6.6;27] | 11.1 [5.9;20.7] | 27.4 [13.6;46.5] | 10 [5;20.5] | 18.2 [11;22.8] | 19 [7.8;44.1] |
| Follow-up duration (years) | | 7.2 [2.6;14] | 4.6 [0.8;12] | 8 [2.9;14] | 7.9 [3.4;14.5] | 5.6 [1.7;11.6] | 7.7 [2;17.2] | 6.6 [1.7;13.1] | 4 [1.6;7.9] | 7.7 [2.1;16.9] | 6.7 [3.4;10.6] | 11.2 [5.2;17.1] | 5.2 [1.5;11] |

Quantitative covariates: Median [Q1;Q3]; qualitative covariates: Effective (Percentage); the order of subgroups from left to right follows the IEI categories I-X of the 2022 IUIS classification available on the end date chosen for inclusion; values *Y* for “yes/present” for real positive values, *N* for “no” is shown to reflect the size of the correct comparison group, excluding “unknown” replies; ages in years; CT, curative / definitive therapy; diagnosis via newborn screening is recorded as subcategory of “no clinical symptoms / lab abnormalities only”, where not all choices of the submenu are shown; examples of “non-genetic definitive tests” are FISH, MLPA, or CGH Arrays.


Age at onset
Age at CD
Age at GD
Number of patients (sqrt scale)
10000
7500
5000
2500
0
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
Age groups, in years


Infection
Immune dysregulation
15360
(61.8%)
2746
(11.1%)
3061
(12.3%)
164
(0.7%)
153
(0.6%)
117
(0.5%)
1803
(7.3%)
103
(0.4%)
219
(0.9%)
14
(0.1%)
46
(0.2%)
1029
(4.1%)
5
(0.0%)
11
(0.0%)
19
(0.1%)
Malignancy
Syndromic features


Genetic diagnosis
No
Yes
IUIS categories
I
II
III
IV
V
VI
VII
VIII
IX
X
Other
1153
1378
3044
1195
1887
13236
1488
683
1250
1298
457
366
596
446
471
1011
43
42
27
3
0
554
0
1000
2000
3000
4000
5000
15000
Number of patients







I. Immunodeficiencies affecting cellular and humoral immunity
II. Combined immunodeficiencies with associated or syndromic features
III. Predominantly antibody deficiencies
IV. Diseases of immune dysregulation
V. Congenital defects of phagocyte number or function
VI. Defects in intrinsic and innate immunity
VII. Autoinflammatory disorders
VIII. Complement deficiencies
IX. Bone marrow failure syndromes
X. Phenocopies of inborn errors of immunity associated with autoantibodies or somatic variants


Unknown/not listed
Splenectomy
Gene therapy
AlloSCT
IgRT (at latest follow-up)
Percentage of patients
100
75
50
25
0
I
II
III
IV
V
VI
VII
VIII
IX
X
Other
IUIS category




*Number at risk*

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 113 | 222 | 128 | 70 | 51 | 44 | 27 | 12 | 4 | 0 | 0 |
| II | 286 | 1487 | 678 | 249 | 105 | 46 | 13 | 1 | 0 | 0 | 0 |
| III | 78 | 2796 | 2354 | 1977 | 2117 | 1868 | 1433 | 946 | 295 | 28 | 0 |
| IV | 29 | 384 | 296 | 139 | 73 | 37 | 20 | 8 | 2 | 0 | 0 |
| V | 80 | 801 | 498 | 258 | 118 | 46 | 17 | 4 | 2 | 0 | 0 |
| VI | 13 | 221 | 124 | 63 | 50 | 42 | 17 | 8 | 1 | 0 | 0 |
| VII | 6 | 244 | 80 | 47 | 32 | 16 | 10 | 3 | 2 | 0 | 0 |
| VIII | 8 | 253 | 293 | 264 | 217 | 147 | 76 | 37 | 16 | 0 | 0 |


Review
(422 citations)
6
1
Technical
(104 citations)
2
2
1
ESID-R
(1221 citations)
15
Country-specific
(2575 citations)
19
13
Disease-specific
(3658 citations)
25

# Supplementary Material

# Inborn errors of immunity: manifestation, treatment, and outcome – an ESID registry 1994-2024 report on 30,628 patients

## Supplementary Text

### Historical evolution of the ESID registry, objectives, structure, and content

The transition from the first, hardcopy-based, to the first online version of the ESID registry (ESID-R) was headed by Bodo Grimbacher, Freiburg, Germany, with the help of Barbara Frisch and Viviane Knerr as well as programmers Dominik Veit and Stephan Rusch in 2000-2004. The biggest hurdles faced during this first restructuration were ethical considerations, data protection, and obtaining industry funding. The second overhaul was conducted by Stephan Ehl, Freiburg, and programmers Benjamin Gathmann and Stephan Rusch in 2014 and focused on content restructuration. The ESID registry (ESID-R) steering group, led by the elected chairperson of the ESID-R working party, oversees all aspects of the evolution of the registry, including the design, operations, financing, and set-up of dedicated studies.

Specific objectives of the ESID-R include:

1. *Collection of epidemiological data:* The registry contains basic information on patients with IEI, including their medical history, diagnosis, genetics, treatment, and disease progression. Data on the prevalence of these rare diseases and the associated health burden are important for political decision-makers.
2. *Analysis and research:* By analyzing the collected data on these rare diseases through multicenter collaboration, researchers can gain new insights into the pathophysiology and treatment of primary immunodeficiencies.
3. *Support of clinical studies and trials:* Registry data can serve as the basis for clinical studies or trials aimed at developing new therapies, improving the treatment of patients affected by those diseases, and for post-marketing surveillance studies of new drugs and medicinal products.
4. *Improving patient care:* Through the analyses and publication of registry data, the registry helps improve IEI patient care by providing physicians and healthcare providers/decision-makers with access to up-to-date information and practices.

Both versions of the ESID-R operating from 2004-2014 and 2014-2024 had the following key features(1):

1. *Database Architecture:* The ESID-R utilizes a sophisticated database architecture to manage the vast amount of data collected from patients. This database is designed to be scalable,

ensuring it can handle the increasing volume of patient records and research findings over time.

2. *Data Security:* Ensuring the security and privacy of patient data is paramount. The ESID-R implements stringent security measures to protect sensitive information, including encryption protocols and access controls
3. *Web-Based Platform:* The ESID-R is accessed through a web-based platform, allowing authorized users to input and access data remotely. This platform is user-friendly and intuitive, facilitating seamless data entry and retrieval processes. Only an up-to-date web-browser and stable internet connection are required to access the system. No additional on-site software needs to be installed/maintained at the documentation centers.
4. *Framework and Technologies:* The ESID-R is built using a combination of programming languages, frameworks, and technologies suited to its specific requirements. Common technologies include SQL databases for data storage, web development frameworks for the user interface, and data analysis tools for reporting and research purposes.

## The three-level content structure

The old version of the online ESID-R (2004-2014) was closed for documentation on June 25, 2014. During the first main revision of the online registry in 2014, a three-level structure was implemented. Level 1 addresses the task of the registry as a simple epidemiological tool. To achieve patient registration by as many centers as possible, the dataset is kept short and simple such that caregivers who know the patient well can fill in the data without consulting the patient chart in much detail. It contains basic epidemiological information, information about main categories of symptoms at initial presentation and information about some key therapies (immunoglobulins, HSCT, gene therapy). The yearly update is restricted to survival and implementation of major therapies. The Level 1 registration also serves to identify patients for additional in-depth studies including interventional trials. Level 2 was designed for long-term studies on certain diseases or disease groups without a predefined end. Level 2 datasets allow registration of a limited number of clinical manifestations and lab values, that are provided on a yearly basis. It was particularly designed to capture longitudinal data in disease groups, for which the molecular basis has not been fully resolved (such as CVID or specific antibody deficiencies). Again, the datasets are kept simple to limit the burden of registration. Level 3 was designed for studies on particular genetically defined diseases based on a study protocol with a defined endpoint. The level 3 dataset can contain very detailed information including grading of symptoms, more sophisticated lab values, detailed treatment information and quality of life data. Registration intervals are at least yearly. Level 3 studies usually offer financial support for the documenting centers.

The level 2 and 3 projects or 'sub-studies' are designed by independent research groups. To apply for implementation of a study in the ESID registry, a statistical evaluation plan, a time and budget forecast, need to be defined in a standardized study proposal, which is assessed for feasibility and to avoid redundancy or competing interests by the registry steering committee and the elected chairperson in regular meetings. There should also be a financial contribution from the PI or research institution to (at least partly) cover the costs associated with the set-up, coordination, data maintenance, and analyses of these registry sub-studies (details on ESID-website, fee structure). When signing the informed consent, patients may choose to have their anonymized data be included

77 either in sub-studies of academic research groups or of pharmaceutical industry-sponsored
78 consortia, or none of them.

## Supplementary Methods

The ESID-R operates based on a technical infrastructure designed to securely receive, store, and enable the analysis of data related to IEI. These data cover, for example, various aspects of the disease, including genetic mutations, clinical symptoms, laboratory test results, imaging findings, and treatment outcomes. Patients with IEI are registered in the web-based database when their disease data are submitted by an authorized physician or healthcare professional or documenting personnel. Centers or sites where patients are cared for are typically university clinics/hospitals and have a data transfer and general data protection regulation (GDPR)-compliant handling agreement and a local IRB approval in place. The data are de-identified and kept strictly confidential to protect patient privacy.

Different measures are applied to avoid duplicates. Firstly, for centers that use the 'personalised version' of the registry, where identifying data is kept on a separate server, the pseudonymization tool (Mainzelliste) creates a notification that this (or a similar) patient seems to have been registered before. The system thereby encourages the documenting person to investigate further, before proceeding with the creation of a new patient documentation. This option is not available for centers who enter pseudmonyms directly. Secondly, persons who sign the consent (patients or parents, next of kin) are always asked whether they have signed a similar consent before. These measures reduce the likelihood of double registrations in the first place. Thirdly, for patients who are transferred from pediatric to adult centers, or who move from one region or country to another, usually the caring hospital is aware of the site where the follow-up is done in the future, and, if this is an ESID-R-documenting center, the patient data can be re-assigned to the new center internally, and follow-up for the adult or relocated patient can be continued in the same documentation under the new center's name.

The Kaplan-Meier curves were generated as described(2). The Kaplan-Meier is done using the start and stop notation to take care of the left truncation effect. Start = age at diagnosis, stop = age at last news, event = living status (0= censored, 1 = deceased first, 2 = curative therapy first). There were 21,206 patients censored, 1,960 patients who deceased first, and 2,901 patients who had a curative therapy first.

## Supplementary Results and Discussion

**Newborn screening and longitudinal patient documentation in the ESID-R.** The ESID-R data structure does not (yet) allow an analysis of improved diagnostic delay and survival in patients diagnosed with SCID in the ESID-R in the NBS (newborn screening) era (supplementary figure 1C). Firstly, NBS for SCID has been performed sequentially over the last decade, but is still not generally available; and secondly, collecting the intended annual follow-up information may cause a system-inherent delay, including underreporting of SCID patients following definitive therapy (or death), before their data are stored in the ESID-R. The ESID-R working party continues to face significant challenges while aiming to integrate data collected over a patient's entire disease course into a single registry, as this ranges from NBS or clinical diagnosis, through different clinical events, such as a form of definitive therapy, and/or chronic treatment, and/or their optional participation in observational sub-studies and on to a cure or until death. The living status at last news from patient is shown in supplementary figure 6.

**The ESID-R in the international landscape of registries for patients with rare immunological diseases.** To depict the current situation of the global IEI registry landscape and participants' motivations, we searched PubMed, communicated with representatives of sister societies around the globe, and performed an online survey in 2024. Of 533 publications retrieved by searching for *primary immunodeficiency patient registry* and exclusion of disease-specific or other secondary sub-studies, the remaining publications showed that a vast majority of IEI/PID registries are national epidemiological databases with a limited temporal and geographical scope regarding longitudinal patient data(2-20). They, naturally, contain a substantially smaller number of patient datasets than the continental ESID registry, which also includes data from patients of some neighboring countries. As such, they are valuable and necessary platforms for the connection of healthcare providers and clinical experts, as well as for health politicians and economists. A relatively recently published overview of the global registry landscape and the burden of IEI/PID from 80 countries evaluated the distribution of IEI/PID diagnoses and other factors such as the diagnostic delay or immunoglobulin treatment in relation to the countries' resources and societal factors such as the rate of consanguinity(21). These data show that the key drivers to implement and maintain an IEI/PID patient registry range from health policy, warranting access to expert care and modern treatments, over patient advocacy, to clinical, biological, and pharmaceutical research and development. Importantly, IPOPI, the global patient organization for IEI, has identified the existence of registries as one of the six key principles of care as part of its PID LIFE Index, a tool to measure the quality of IEI/PID healthcare in a country(22). To analyze the policy of patient inclusion and obtain feedback from documenting physicians or study nurses, we designed a survey distributed through ESID in 2024. A total of 43 physicians from 29 different European and non-European countries participated in this survey (Supplementary Table 5). Seventy percent of respondents (30/43) said they would exclusively register their patients into the ESID-R; 30% of the survey respondents (13/43) said they would also enter patient data into one of the following disease-specific (other than general IEI/PID) registries: *Eurofever, Severe Chronic Neutropenia International Registry (SCNIR), Juvenile Inflammatory Rheumatism (JIR) Cohort,* and the registry of the *EBMT/Center for International Blood and Marrow Transplant Research (CIBMTR)*. Motivations for entering data into the ESID-R included collaborative research (88%), networking (84%), taking part in academic or pharmaceutical studies (84% and 72%), and improvements in patient care (72%) and for IEI education purposes. Reasons given for not entering patient data into the ESID-R were: lack of personnel (84%), legal challenges

regarding data transfer (37%), no obvious local benefit (23%), and concerns about small countries being underrepresented (14%). Survey participants stated that they would like a simplified version of the patient consent form, easy interoperability between national registries and the ESID-R, and grant incentives for entering patient data, especially if these were needed at a higher level of granularity.

**Human Phenotype Ontology (HPO) in IEI/PID, and potential benefit of integrating HPO into the ESID-R.** The Human Phenotype Ontology (HPO) comprehensively organizes and defines the phenotypic features of human disease, supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms(23). Currently, the HPO terminology for IEI/PID still needs to be further developed with help of the community of clinical immunologists and researchers focusing on IEI/PID: *i.e.*, new HPO terms for relevant phenotypic features to be added, and existing HPO terms to be revised, such that the definitions and hierarchical placement in the HPO reflect current knowledge(24). The HPO can be used with the Global Alliance for Genomics and Health (GA4GH) Phenopacket Schema to represent not only phenotypic features, but also measurements, biopsies, and treatments over the entire time course of a disease(25). Collections of phenopackets may support translational research in immunology by providing standardized input data for software programs designed to identify genotype-phenotype correlations, and characterize disease subtypes(26). Integrating the HPO terminology into the ESID-R, would inspire studies within or across IUIS categories, especially in monogenic entities. To make full use of the HPO, better systems for simple but comprehensive and accurate data entry are needed.

173 # Supplementary Material (Tables)

174 **Supplementary Table 1. Contributing countries, sorted by the calculated prevalence per 100,000**
175 **inhabitants.**

| Country | Registered patients | Genetically diagnosed (%) | Registered patients/100,000 inhabitants | Prevalence /100,000 inhabitants |
|---|---|---|---|---|
| Slovakia | 794 | 38.41% | 14.56 | 14.32 |
| France | 9,113 | 48.6% | 13.59 | 10.99 |
| Belgium | 1,333 | 17.78% | 11.61 | 11.36 |
| Switzerland | 658 | 44.68% | 7.67 | 7.55 |
| Slovenia | 129 | 62.79% | 6.18 | 6.18 |
| Germany | 5,056 | 44.96% | 6.08 | 5.73 |
| United Kingdom | 3,949 | 31.22% | 5.91 | 5.51 |
| Ireland | 280 | 39.29% | 5.67 | 5.48 |
| Portugal | 569 | 47.1% | 5.54 | 5.00 |
| Czechia | 573 | 52.88% | 5.37 | 4.98 |
| Netherlands | 715 | 26.85% | 4.13 | 3.96 |
| Greece | 387 | 48.32% | 3.61 | 3.46 |
| Hungary | 315 | 47.94% | 3.22 | 2.68 |
| Austria | 286 | 51.05% | 3.22 | 3.03 |
| Bulgaria | 175 | 38.29% | 2.51 | 2.42 |
| Belarus | 228 | 82.02% | 2.41 | 1.92 |
| Lithuania | 63 | 6.35% | 2.26 | 2.12 |
| Spain | 1,008 | 50.2% | 2.14 | 2.01 |
| Poland | 813 | 66.42% | 2.14 | 1.86 |
| Estonia | 26 | 11.54% | 1.96 | 1.88 |
| Italy | 1,036 | 27.7% | 1.72 | 1.58 |
| Iran | 1,284 | 9.35% | 1.55 | 1.39 |

| Country | Registered patients | Genetically diagnosed (%) | Registered patients/100,000 inhabitants | Prevalence /100,000 inhabitants |
|---|---|---|---|---|
| Denmark | 77 | 25.97% | 1.32 | 1.31 |
| Serbia | 82 | 34.15% | 1.18 | 1.17 |
| Turkey | 874 | 39.02% | 1.05 | 0.98 |
| Croatia | 36 | 58.33% | 0.89 | 0.79 |
| Egypt | 512 | 43.95% | 0.51 | 0.41 |
| Ukraine | 140 | 82.86% | 0.32 | 0.29 |
| Romania | 50 | 76% | 0.26 | 0.20 |
| Israel | 5 | 80% | 0.06 | 0.06 |
| Russia | 59 | 93.22% | 0.04 | 0.03 |
| Bosnia and Herzegowina | 1 | 100% | 0.03 | 0.03 |
| Sweden | 2 | 100% | 0.02 | 0.02 |

Of note, the ESID-R has no means to influence the balance of data entry per country or center, resulting in differences of the proportion of children, adolescent and adult patients, the “weight” given to certain diseases at some centers and their potential overrepresentation. Although measures were taken and found to be successful to unify the classification of non-genetic diseases such as common variable immune deficiency or selective IgA deficiency by applying the ESID registry working definitions for making a clinical diagnosis, the variance in the “epidemiological activity” of some centers as compared to others remains.

185 **Supplementary Table 2. Underlying and main causes of death.**

| Covariate | Whole cohort N=30628 | CID (I) N=2531 | Syndromic (II) N=4239 | PAD (III) N=15123 | PIRD (IV) N=2171 | Phagocyte (V) N=2548 | Innate (VI) N=823 | AIS (VII) N=1042 | Complement (VIII) N=1482 | BMF (IX) N=85 | Phenocopies (X) N=30 | other N=554 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Underlying cause of death: Infection | 989 (32.8%) | 302 (51.3%) | 192 (31.7%) | 232 (22.2%) | 99 (29.3%) | 89 (34.6%) | 47 (54%) | 10 (43.5%) | 4 (28.6%) | 9 (40.9%) | 0 (0%) | 5 (17.9%) |
| Underlying cause of death: Malignancy | 456 (15.1%) | 34 (5.8%) | 154 (25.5%) | 199 (19%) | 28 (8.3%) | 22 (8.6%) | 8 (9.2%) | 0 (0%) | 3 (21.4%) | 1 (4.5%) | 3 (100%) | 4 (14.3%) |
| Underlying cause of death: Immune dysregulation | 350 (11.6%) | 47 (8%) | 54 (8.9%) | 90 (8.6%) | 122 (36.1%) | 16 (6.2%) | 7 (8%) | 7 (30.4%) | 2 (14.3%) | 1 (4.5%) | 0 (0%) | 4 (14.3%) |
| Underlying cause of death: transplantation | 371 (12.3%) | 154 (26.1%) | 48 (7.9%) | 30 (2.9%) | 87 (25.7%) | 33 (12.8%) | 9 (10.3%) | 4 (17.4%) | 2 (14.3%) | 3 (13.6%) | 0 (0%) | 1 (3.6%) |
| Underlying cause of death: Other | 434 (14.8%) | 46 (8.6%) | 104 (17.3%) | 197 (18.9%) | 22 (6.9%) | 30 (12.1%) | 22 (25.6%) | 3 (13%) | 1 (7.1%) | 5 (22.7%) | 0 (0%) | 4 (14.8%) |
| Main cause of death: Septic Shock | 405 (13.4%) | 82 (13.9%) | 75 (12.4%) | 127 (12.1%) | 37 (10.9%) | 38 (14.8%) | 33 (37.9%) | 8 (34.8%) | 3 (21.4%) | 2 (9.1%) | 0 (0%) | 0 (0%) |
| Main cause of death: Renal Failure | 54 (1.8%) | 10 (1.7%) | 12 (2%) | 20 (1.9%) | 6 (1.8%) | 3 (1.2%) | 2 (2.3%) | 0 (0%) | 0 (0%) | 1 (4.5%) | 0 (0%) | 0 (0%) |
| Main cause of death: Neurological Complications | 183 (6.1%) | 28 (4.8%) | 24 (4%) | 48 (4.6%) | 43 (12.7%) | 18 (7%) | 15 (17.2%) | 2 (8.7%) | 1 (7.1%) | 1 (4.5%) | 0 (0%) | 3 (10.7%) |
| Main cause of death: Relapse of Malignancy | 200 (6.6%) | 17 (2.9%) | 55 (9.1%) | 89 (8.5%) | 16 (4.7%) | 12 (4.7%) | 5 (5.7%) | 0 (0%) | 1 (7.1%) | 2 (9.1%) | 2 (66.7%) | 1 (3.6%) |
| Main cause of death: GvHD | 82 (2.7%) | 44 (7.5%) | 10 (1.7%) | 5 (0.5%) | 12 (3.6%) | 10 (3.9%) | 1 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Main cause of death: PTLD | 25 (0.8%) | 10 (1.7%) | 7 (1.2%) | 1 (0.1%) | 5 (1.5%) | 1 (0.4%) | 1 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Main cause of death: Heart Failure | 125 (4.2%) | 17 (2.9%) | 23 (3.8%) | 49 (4.7%) | 13 (3.8%) | 14 (5.4%) | 3 (3.4%) | 3 (13%) | 1 (7.1%) | 0 (0%) | 2 (66.7%) | 0 (0%) |
| Main cause of death: Multiple Organ Failure | 368 (12.2%) | 89 (15.1%) | 64 (10.6%) | 83 (7.9%) | 74 (21.9%) | 31 (12.1%) | 19 (21.8%) | 3 (13%) | 0 (0%) | 4 (18.2%) | 0 (0%) | 1 (3.6%) |
| Main cause of death: Surgical Complications | 19 (0.6%) | 1 (0.2%) | 7 (1.2%) | 5 (0.5%) | 0 (0%) | 3 (1.2%) | 2 (2.3%) | 1 (4.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Main cause of death: Veno Occlusive Disorder | 22 (0.7%) | 11 (1.9%) | 2 (0.3%) | 0 (0%) | 6 (1.8%) | 2 (0.8%) | 0 (0%) | 1 (4.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |

| Covariate | Whole cohort | CID (I) | Syndromic (II) | PAD (III) | PIRD (IV) | Phagocyte (V) | Innate (VI) | AIS (VII) | Complement (VIII) | BMF (IX) | Phenocopies (X) | other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Main cause of death: Graft Rejection | 45 (1.5%) | 21 (3.6%) | 5 (0.8%) | 3 (0.3%) | 7 (2.1%) | 5 (1.9%) | 2 (2.3%) | 1 (4.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.6%) |
| Main cause of death: Respiratory Failure | 640 (21.2%) | 156 (26.5%) | 174 (28.8%) | 160 (15.3%) | 70 (20.7%) | 49 (19.1%) | 10 (11.5%) | 6 (26.1%) | 3 (21.4%) | 6 (27.3%) | 3 (100%) | 3 (10.7%) |
| Main cause of death: Haemorrhage | 119 (4%) | 15 (2.5%) | 30 (5%) | 36 (3.4%) | 20 (5.9%) | 7 (2.7%) | 6 (6.9%) | 3 (13%) | 0 (0%) | 1 (4.5%) | 0 (0%) | 1 (3.6%) |
| Main cause of death: Drug Toxicity | 11 (0.4%) | 2 (0.3%) | 3 (0.5%) | 4 (0.4%) | 2 (0.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Main cause of death: Liver Failure | 72 (2.4%) | 10 (1.7%) | 14 (2.3%) | 34 (3.3%) | 8 (2.4%) | 3 (1.2%) | 3 (3.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Main cause of death: Thrombosis | 5 (0.2%) | 1 (0.2%) | 0 (0%) | 4 (0.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Main cause of death: Other | 238 (7.9%) | 24 (4.1%) | 35 (5.8%) | 103 (9.8%) | 41 (12.1%) | 20 (7.8%) | 8 (9.2%) | 2 (8.7%) | 3 (21.4%) | 0 (0%) | 0 (0%) | 2 (7.1%) |

Effective (Percentage); the order of subgroups from left to right follows the IEI categories I-X of the 2022 IUIS classification available on the end date chosen for inclusion with abbreviations for combined immunodeficiencies (CID), CID with syndromic features (Syndromic), primary antibody deficiencies (PAD), diseases with immune dysregulation or primary immune regulatory disorders (PIRD), diseases of phagocyte number or function (Phagocyte), disorders of innate immunity (Innate), autoinflammatory syndromes (AIS), complement deficiencies (Complement), bone marrow failure syndromes (BMF), and phenocopies.

193 **Supplementary Table 3. Therapy.**

| Covariate | Values | Whole cohort N=30628 | CID (I) N=2531 | Syndromic (II) N=4239 | PAD (III) N=15123 | PIRD (IV) N=2171 | Phagocyte (V) N=2548 | Innate (VI) N=823 | AIS (VII) N=1042 | Complement (VIII) N=1482 | BMF (IX) N=85 | Phenocopies (X) N=30 | other N=554 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currently under IgRT | N | 13701 (57.5%) | 1039 (63.8%) | 2280 (74.9%) | 4316 (34.9%) | 1290 (79.2%) | 1864 (96.5%) | 525 (82.9%) | 770 (93.4%) | 1269 (98.2%) | 48 (85.7%) | 20 (95.2%) | 280 (73.9%) |
| | Y | 10107 (42.5%) | 589 (36.2%) | 764 (25.1%) | 8054 (65.1%) | 339 (20.8%) | 68 (3.5%) | 108 (17.1%) | 54 (6.6%) | 23 (1.8%) | 8 (14.3%) | 1 (4.8%) | 99 (26.1%) |
| IgRT: route | Intravenous | 6410 (51%) | 572 (65.3%) | 600 (58.8%) | 4643 (48.2%) | 324 (63.9%) | 87 (73.1%) | 66 (43.7%) | 41 (57.7%) | 11 (33.3%) | 8 (66.7%) | 2 (66.7%) | 56 (41.2%) |
| | Subcutaneous | 6119 (48.7%) | 297 (33.9%) | 416 (40.8%) | 4973 (51.6%) | 181 (35.7%) | 32 (26.9%) | 85 (56.3%) | 30 (42.3%) | 21 (63.6%) | 4 (33.3%) | 1 (33.3%) | 79 (58.1%) |
| | Intramuscular | 17 (0.1%) | 1 (0.1%) | 2 (0.2%) | 12 (0.1%) | 1 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| | Push (s.c.) | 24 (0.2%) | 6 (0.7%) | 2 (0.2%) | 14 (0.1%) | 1 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.7%) |
| Age at first IgRT | | 19.3 [5.2;41.8] | 2 [0.5;10.3] | 5 [1.3;11.5] | 28.6 [8.7;46.7] | 10.2 [4.2;19.1] | 6.3 [2.1;11.8] | 6.7 [2.3;13.3] | 5.6 [1.9;15.9] | 9.7 [5.6;18] | 1.6 [0.7;7.3] | 7 [6.1;14] | 17.1 [5.9;45.2] |
| AlloSCT | N | 27263 (89%) | 1261 (49.8%) | 3783 (89.2%) | 14907 (98.6%) | 1518 (69.9%) | 1907 (74.8%) | 785 (95.4%) | 1010 (96.9%) | 1480 (99.9%) | 52 (61.2%) | 28 (93.3%) | 532 (96%) |
| | Y | 3365 (11%) | 1270 (50.2%) | 456 (10.8%) | 216 (1.4%) | 653 (30.1%) | 641 (25.2%) | 38 (4.6%) | 32 (3.1%) | 2 (0.1%) | 33 (38.8%) | 2 (6.7%) | 22 (4%) |
| Age at first AlloSCT | | 2 [0.6;8.1] | 0.7 [0.4;1.7] | 2.3 [1.1;6.5] | 9.5 [3.5;17.7] | 2.4 [0.5;8.9] | 6.1 [2.2;13.1] | 7.8 [3.3;10.7] | 4 [1.5;7] | 11.4 [10.5;12.3] | 10 [5.1;16] | 7.9 [6.6;9.2] | 7.4 [4.9;14.4] |
| Gene therapy | N | 29070 (99.7%) | 2327 (97.9%) | 4011 (99.6%) | 14465 (100%) | 2086 (100%) | 2452 (99.6%) | 793 (100%) | 923 (100%) | 1411 (100%) | 81 (100%) | 30 (100%) | 491 (100%) |
| | Y | 77 (0.3%) | 50 (2.1%) | 17 (0.4%) | 0 (0%) | 0 (0%) | 10 (0.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Age at first gene therapy | | 2.3 [0.8;4.6] | 0.9 [0.6;2.9] | 3.6 [2.8;7.4] | NA [NA;NA] | NA [NA;NA] | 15.1 [7.7;22.9] | NA [NA;NA] | NA [NA;NA] | NA [NA;NA] | NA [NA;NA] | NA [NA;NA] | NA [NA;NA] |
| Splenectomy | N | 19732 | 1565 | 2681 (96.8%) | 9846 | 1620 | 1485 | 603 | 753 (99.1%) | 789 (99.9%) | 55 | 21 (84%) | 314 (98.7%) |

| Covariate | Values | Whole cohort | CID (I) | Syndromic (II) | PAD (III) | PIRD (IV) | Phagocyte (V) | Innate (VI) | AIS (VII) | Complement (VIII) | BMF (IX) | Phenocopies (X) | other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | (97.8%) | (98.1%) | | (97.9%) | (94.8%) | (99.3%) | (99.7%) | | | (100%) | | |
| | Y | 453 (2.2%) | 30 (1.9%) | 90 (3.2%) | 216 (2.1%) | 89 (5.2%) | 10 (0.7%) | 2 (0.3%) | 7 (0.9%) | 1 (0.1%) | 0 (0%) | 4 (16%) | 4 (1.3%) |
| Age at splenectomy | | 17.9 [7.3;33.3] | 16 [9;24] | 5.4 [2.3;8] | 31.3 [20.1;42] | 11.3 [6.7;20.2] | 8.9 [4.5;21.3] | 2.8 [2.8;2.8] | 21.2 [17.9;36.1] | 33.9 [33.9;33.9] | NA [NA;NA] | 7.2 [4.6;8.6] | 19.3 [15.7;25.3] |

Quantitative covariates: Median [Q1;Q3]; qualitative covariates: Effective (Percentage)

197 **Supplementary Table 4. Sub-analysis of IEI/PID diagnoses in patients who died before the age of 5**
198 **years in two subcategories of IEI/PID.**

| IEI/PID diagnoses underlying death before the age of 5 years in the category *diseases with immune dysregulation* (synonymously used as primary immune regulatory disorders, *PIRD*) \| *n*= | |
|---|---|
| Familial hemophagocytic lymphohistiocytosis syndromes (FHLH)* | 44 |
| X-linked lymphoproliferative syndrome (XLP)* | 10 |
| FOXP3 deficiency (IPEX) | 4 |
| Autoimmune lymphoproliferative syndrome (ALPS) | 3 |
| Early-onset inflammatory bowel disease | 2 |
| Griscelli syndrome, type 2* | 2 |
| Unclassified disorders of immune dysregulation | 2 |
| APECED / APS1 with CMC - Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) | 1 |
| Chediak Higashi syndrome* | 1 |
| IPEX-like disease | 1 |
| *proportion of patients with risk of hemophagocytic lymphohistiocytosis (HLH) | 81·4% |
| | |
| IEI/PID diagnoses underlying death before the age of 5 years in category *disorders of innate or intrinsic immunity (*abbreviated *Innate)* \| *n*= | |
| Defects of TLR/NFkappa-B signalling | 7 |
| Isolated congenital asplenia | 7 |
| Defects with susceptibility to mycobacterial infection (MSMD) | 4 |
| ZNFX1 deficiency | 2 |
| Asplenia syndrome (Ivemark syndrome) | 1 |
| Chronic mucocutaneous candidiasis (CMC) | 1 |
| IRF9 deficiency | 1 |
| Unclassified defects in innate immunity | 1 |

199

200

201 **Supplementary Table 5. Institutions of participants of the 2024 ESID-R survey on the**
202 **international IEI/PID registry landscape.**

| Western Europe | Eastern Europe | Other countries |
|---|---|---|
| Denmark (Copenhagen) | Armenia (Yerevan) | Australia (Melbourne) |
| Finland (Helsinki) | Belarus (Minsk) | Brazil (São Paulo) |
| Germany<br>(Dresden, Freiburg, Leipzig, Munich) | Bulgaria (Sofia) | Canada (Halifax) |
| Ireland (Dublin) | Czech Republic (Prague) | Egypt (Cairo) |
| Italy (Milan) | Georgia (Tbilisi) | Iran (Teheran) |
| Portugal (Coimbra) | Hungary (Budapest) | Sudan (Khartoum) |
| Spain (Barcelona) | Latvia (Riga) | Turkey (Istanbul) |
| Sweden (Jönköping) | Romania (Bucharest) | USA (Philadelphia) |
| Switzerland (Geneva, Zurich) | Russia (Moscow) | |
| United Kingdom (Sheffield) | Serbia (Belgrade) | |
| | Ukraine (Kyiv) | |

203 *The survey participants chose to reply (or not) to a survey which had been distributed via the ESID-R*
204 *listserv and was also posted on the website during the summer of 2024.*

205

206
207

# Supplementary Material (Figures)

**Supplementary Figure 1A. Cumulative number of patients registered in the ESID-R.**




The total number shown here is 31,889 patients (male *n*=17,515; female *n*=14,363; unknown *n*=11), before exclusion of those discharged (*n*=538), those with secondary immunodeficiency (*n*=417) and those without a definitive diagnosis of IEI/PID (*n*=306). Data shown for the **online** Registry only. Data from the very first version (hardcopy) was not transferred to the first online registry, but newly entered.

According to "The Source https://esid.org/wp-content/uploads/2024/03/ESID_TheSource_2003.pdf" the total number in 2003 was 9707 pts.

**Supplementary Figure 1B. Cumulative number of ESID-R participating centers.**



221 **Supplementary Figure 1C. Diagnostic delay (in years from first manifestation to clinical diagnosis**
222 **and from clinical diagnosis to genetic diagnosis) over the last 20 years of the ESID-R.** The y-axis
223 shows the year of clinical/genetic diagnosis.




224

225

226 **Supplementary Figure 2. IEI/PID minimal prevalence map according to ESID-R patient numbers and**
227 **the 2019 population (same data as in Supplementary Table 1).**




228

229

**Supplementary Figure 3. IEI/PID distribution, nested pie chart for IUIS category, diagnosis, and gene.** This is merely a sketch, please see the interactive version of the figure with all data labels and patient numbers shown on mouse-over at https://esid.org/html-pages/Suppl%20Fig%203_ESID_30k_sunburst_PID.html .



236 **Supplementary Figure 4. Top 50 genetic diagnoses of IEI/PID patients recorded in the ESID-R.** The
237 top 50 genes mutated in ESID-R patients with monogenic IEI/PID are shown with respective patient
238 numbers in descending order.




239

240

**Supplementary Figure 5. Survival probabilities of main categories of IEI/PID and the living status at last news.** Inverse cumulative incidence curves and confidence intervals as described and referenced above. Start = age at diagnosis, stop = age at last news, event = living status (0= censored, 1 = deceased first, 2 = curative therapy first). There were 21,206 patients censored, 1,960 patients who deceased first, and 2,901 patients who had a curative therapy first (not showing deaths after curative therapy); roman numbers refer to the IUIS categories for IEI/PID as listed in Figure 2B.




*Number at risk*

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 113 | 222 | 128 | 70 | 51 | 44 | 27 | 12 | 4 | 0 | 0 |
| II | 286 | 1487 | 678 | 249 | 105 | 46 | 13 | 1 | 0 | 0 | 0 |
| III | 78 | 2796 | 2354 | 1977 | 2117 | 1868 | 1433 | 946 | 295 | 28 | 0 |
| IV | 29 | 384 | 296 | 139 | 73 | 37 | 20 | 8 | 2 | 0 | 0 |
| V | 80 | 801 | 498 | 258 | 118 | 46 | 17 | 4 | 2 | 0 | 0 |
| VI | 13 | 221 | 124 | 63 | 50 | 42 | 17 | 8 | 1 | 0 | 0 |
| VII | 6 | 244 | 80 | 47 | 32 | 16 | 10 | 3 | 2 | 0 | 0 |
| VIII | 8 | 253 | 293 | 264 | 217 | 147 | 76 | 37 | 16 | 0 | 0 |

253 **Supplementary Figure 6. Living status of patients at the year of last news in the ESID-R captured**
254 **until March 2024.**
255




256
257
258 "Last news" is the date when the patient was last seen or his/her condition was reported (by
259 telephone or medical report). It is not the documentation date. Together, these data reflect the
260 overall follow-up rate and living status of patients up to the time point of data closure in March 2024.
261
262

263 **Supplementary Figure 7.** Countries with national patient registries or national sub-registries within
264 the ESID-R according to the 2024 ESID survey (all participating IEI/PID centers worldwide are listed in
265 Suppl. Table 5).

266

267

268

# Supplementary References


1. Scheible R, Rusch S, Guzman D, Mahlaoui N, Ehl S, Kindle G. The NEW ESID online database network. *Bioinformatics* 2019;**35**(24):5367-69 doi: 10.1093/bioinformatics/btz525.

2. Alligon M, Mahlaoui N, Bouaziz O. Pitfalls in time-to-event analysis of registry data: a tutorial based on simulated and real cases. *Front Epidemiol* 2024;**4**:1386922 doi: 10.3389/fepid.2024.1386922.

3. Abd Hamid IJ, Azman NA, Gennery AR, Mangantig E, Hashim IF, Zainudeen ZT. Systematic Review of Primary Immunodeficiency Diseases in Malaysia: 1979-2020. *Frontiers in immunology* 2020;**11**:1923 doi: 10.3389/fimmu.2020.01923.

4. Aghamohammadi A, Moein M, Farhoudi A, Pourpak Z, Rezaei N, Abolmaali K, Movahedi M, Gharagozlou M, Ghazi BM, Mahmoudi M, Mansouri D, Arshi S, Trash NJ, Akbari H, Sherkat R, Hosayni RF, Hashemzadeh A, Mohammadzadeh I, Amin R, Kashef S, Alborzi A, Karimi A, Khazaei H. Primary immunodeficiency in Iran: first report of the National Registry of PID in Children and Adults. *Journal of clinical immunology* 2002;**22**(6):375-80 doi: 10.1023/a:1020660416865.

5. Al-Herz W, Al-Ahmad M, Al-Khabaz A, Husain A, Sadek A, Othman Y. The Kuwait National Primary Immunodeficiency Registry 2004-2018. *Frontiers in immunology* 2019;**10**:1754 doi: 10.3389/fimmu.2019.01754.

6. El-Helou SM, Biegner AK, Bode S, Ehl SR, Heeg M, Maccari ME, Ritterbusch H, Speckmann C, Rusch S, Scheible R, Warnatz K, Atschekzei F, Beider R, Ernst D, Gerschmann S, Jablonka A, Mielke G, Schmidt RE, Schurmann G, Sogkas G, Baumann UH, Klemann C, Viemann D, von Bernuth H, Kruger R, Hanitsch LG, Scheibenbogen CM, Wittke K, Albert MH, Eichinger A, Hauck F, Klein C, Rack-Hoch A, Sollinger FM, Avila A, Borte M, Borte S, Fasshauer M, Hauenherm A, Kellner N, Muller AH, Ulzen A, Bader P, Bakhtiar S, Lee JY, Hess U, Schubert R, Wolke S, Zielen S, Ghosh S, Laws HJ, Neubert J, Oommen PT, Honig M, Schulz A, Steinmann S, Schwarz K, Duckers G, Lamers B, Langemeyer V, Niehues T, Shai S, Graf D, Muglich C, Schmalzing MT, Schwaneck EC, Tony HP, Dirks J, Haase G, Liese JG, Morbach H, Foell D, Hellige A, Wittkowski H, Masjosthusmann K, Mohr M, Geberzahn L, Hedrich CM, Muller C, Rosen-Wolff A, Roesler J, Zimmermann A, Behrends U, Rieber N, Schauer U, Handgretinger R, Holzer U, Henes J, Kanz L, Boesecke C, Rockstroh JK, Schwarze-Zander C, Wasmuth JC, Dilloo D, Hulsmann B, Schonberger S, Schreiber S, Zeuner R, Ankermann T, von Bismarck P, Huppertz HI, Kaiser-Labusch P, Greil J, Jakoby D, Kulozik AE, Metzler M, Naumann-Bartsch N, Sobik B, Graf N, Heine S, Kobbe R, Lehmberg K, Muller I, Herrmann F, Horneff G, Klein A, Peitz J, Schmidt N, Bielack S, Gross-Wieltsch U, Classen CF, Klasen J, Deutz P, Kamitz D, Lassay L, Tenbrock K, Wagner N, Bernbeck B, Brummel B, Lara-Villacanas E, Munstermann E, Schneider DT, Tietsch N, Westkemper M, Weiss M, Kramm C, Kuhnle I, Kullmann S, Girschick H, Specker C, Vinnemeier-Laubenthal E, Haenicke H, Schulz C, Schweigerer L, Muller TG, Stiefel M, Belohradsky BH, Soetedjo V, Kindle G, Grimbacher B. The German National Registry of Primary Immunodeficiencies (2012-2017). *Frontiers in immunology* 2019;**10**:1272 doi: 10.3389/fimmu.2019.01272.

7. group CTFPs. The French national registry of primary immunodeficiency diseases. *Clinical immunology* 2010;**135**(2):264-72 doi: 10.1016/j.clim.2010.02.021.

8. Lougaris V, Pession A, Baronio M, Soresina A, Rondelli R, Gazzurelli L, Benvenuto A, Martino S, Gattorno M, Biondi A, Zecca M, Marinoni M, Fabio G, Aiuti A, Marseglia G,

Putti MC, Agostini C, Lunardi C, Tommasini A, Bertolini P, Gambineri E, Consolini R, Matucci A, Azzari C, Danieli MG, Paganelli R, Duse M, Cancrini C, Moschese V, Chessa L, Spadaro G, Civino A, Vacca A, Cardinale F, Martire B, Carpino L, Trizzino A, Russo G, Cossu F, Badolato R, Pietrogrande MC, Quinti I, Rossi P, Ugazio A, Pignata C, Plebani A. The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999-2019). *Journal of clinical immunology* 2020;**40**(7):1026-37 doi: 10.1007/s10875-020-00844-0.

9. Ludviksson BR, Sigurdardottir ST, Johannsson JH, Haraldsson A, Hardarson TO. Epidemiology of Primary Immunodeficiency in Iceland. *Journal of clinical immunology* 2015;**35**(1):75-9 doi: 10.1007/s10875-014-0107-3.

10. Massaad MJ, Zainal M, Al-Herz W. Frequency and Manifestations of Autoimmunity Among Children Registered in the Kuwait National Primary Immunodeficiency Registry. *Frontiers in immunology* 2020;**11**:1119 doi: 10.3389/fimmu.2020.01119.

11. Matamoros Flori N, Mila Llambi J, Espanol Boren T, Raga Borja S, Fontan Casariego G. Primary immunodeficiency syndrome in Spain: first report of the National Registry in Children and Adults. *Journal of clinical immunology* 1997;**17**(4):333-9 doi: 10.1023/a:1027382916924.

12. Mellouli F, Mustapha IB, Khaled MB, Besbes H, Ouederni M, Mekki N, Ali MB, Largueche B, Hachicha M, Sfar T, Gueddiche N, Barsaoui S, Sammoud A, Boussetta K, Becher SB, Meherzi A, Guandoura N, Boughammoura L, Harbi A, Amri F, Bayoudh F, Jaballah NB, Tebib N, Bouaziz A, Mahfoudh A, Aloulou H, Mansour LB, Chabchoub I, Boussoffara R, Chemli J, Bouguila J, Hassayoun S, Hammami S, Habboul Z, Hamzaoui A, Ammar J, Barbouche MR, Bejaoui M. Report of the Tunisian Registry of Primary Immunodeficiencies: 25-Years of Experience (1988-2012). *Journal of clinical immunology* 2015;**35**(8):745-53 doi: 10.1007/s10875-015-0206-9.

13. Michos A, Raptaki M, Tantou S, Tzanoudaki M, Spanou K, Liatsis M, Constantinidou N, Paschali E, Varela I, Moraloglou O, Bakoula C, Kanariou M. Primary immunodeficiency diseases: a 30-year patient registry from the referral center for primary immunodeficiencies in Greece. *Journal of clinical immunology* 2014;**34**(7):836-43 doi: 10.1007/s10875-014-0066-8.

14. Moore A, Blumenthal KG, Chambers C, Namazy J, Nowak-Wegrzyn A, Phillips EJ, Rider NL. Improving Clinical Practice Through Patient Registries in Allergy and Immunology. *J Allergy Clin Immunol Pract* 2024;**12**(10):2599-609 doi: 10.1016/j.jaip.2024.05.003.

15. Mukhina AA, Kuzmenko NB, Rodina YA, Kondratenko IV, Bologov AA, Latysheva TV, Prodeus AP, Pampura AN, Balashov DN, Ilyina NI, Latysheva EA, Deordieva EA, Shvets OA, Deripapa EV, Abramova IN, Pashenko OE, Vahlyarskaya SS, Zinovyeva NV, Zimin SB, Skorobogatova EV, Machneva EB, Fomina DS, Ipatova MG, Barycheva LY, Khachirova LS, Tuzankina IA, Bolkov MA, Shakhova NV, Kamaltynova EM, Sibgatullina FI, Guseva MN, Kuznetsova RN, Milichkina AM, Totolian AA, Kalinina NM, Goltsman EA, Sulima EI, Kutlyanceva AY, Moiseeva AA, Khoreva AL, Nesterenko Z, Tymofeeva EV, Ermakova A, Proligina DD, Kalmetieva LR, Davletbaieva GA, Mirsayapova IA, Richkova OA, Kuzmicheva KP, Grakhova MA, Yudina NB, Orlova EA, Selezneva OS, Piskunova SG, Samofalova TV, Bukina TV, Pechkurova AD, Migacheva N, Zhestkov A, Barmina EV, Parfenova NA, Isakova SN, Averina EV, Sazonova IV, Starikova SY, Shilova TV, Asekretova TV, Suprun RN, Kleshchenko EI, Lebedev VV, Demikhova EV, Demikhov VG, Kalinkina VA, Gorenkova AV, Duryagina SN, Pavlova TB, Shinkareva VM, Smoleva IV,

366 Aleksandrova TP, Bambaeva ZV, Philippova MA, Gracheva EM, Tcyvkina GI,
367 Efremenkov AV, Mashkovskaya D, Yarovaya IV, Alekseenko VA, Fisyun IV,
368 Molokova GV, Troitskya EV, Piatkina LI, Vlasova EV, Ukhanova O, Chernishova EG,
369 Vasilieva M, Laba OM, Volodina E, Safonova EV, Voronin KA, Gurkina MV,
370 Rumyantsev AG, Novichkova GA, Shcherbina AY. Primary Immunodeficiencies in
371 Russia: Data From the National Registry. *Frontiers in immunology* 2020;**11**:1491 doi:
372 10.3389/fimmu.2020.01491.

373 16. Pickett G, Motazedi T, Kutac C, Cahill G, Cunnigham-Rundles C, Fuleihan RL, Sullivan
374 KE, Rider NL. Infection Phenotypes Among Patients with Primary Antibody Deficiency
375 Mined from a US Patient Registry. *Journal of clinical immunology* 2021;**41**(2):374-81
376 doi: 10.1007/s10875-020-00916-1.

377 17. Rhim JW, Kim KH, Kim DS, Kim BS, Kim JS, Kim CH, Kim HM, Park HJ, Pai KS, Son
378 BK, Shin KS, Oh MY, Woo YJ, Yoo Y, Lee KS, Lee KY, Lee CG, Lee JS, Chung EH,
379 Choi EH, Hahn YS, Park HY, Kim JG. Prevalence of primary immunodeficiency in
380 Korea. *J Korean Med Sci* 2012;**27**(7):788-93 doi: 10.3346/jkms.2012.27.7.788.

381 18. Ruffner MA, Group UBW, Sullivan KE. Complications Associated with Underweight
382 Primary Immunodeficiency Patients: Prevalence and Associations Within the
383 USIDNET Registry. *Journal of clinical immunology* 2018;**38**(3):283-93 doi:
384 10.1007/s10875-018-0492-0.

385 19. Volokha A, Bondarenko A, Chernyshova L, Hilfanova A, Stepanovskiy Y, Boyarchuk O,
386 Kostyuchenko L. Impact of the J Project on progress of primary immunodeficiency
387 care in Ukraine. *Cent Eur J Immunol* 2021;**46**(2):250-57 doi:
388 10.5114/ceji.2021.108183.

389 20. Seminario G, Gonzalez-Serrano ME, Aranda CS, Grumach AS, Segundo GRS, Regairaz
390 L, Cardona AA, Group LR, Becerra JCA, Poli C, King A, Fernandes FR, Leiva L,
391 Franco JL, Espinosa-Rosales FJ, Sorensen R, Costa Carvalho BT, Bezrodnik L,
392 Condino-Neto A. The Latin American Society for Immunodeficiencies Registry.
393 *Journal of clinical immunology* 2024;**45**(1):28 doi: 10.1007/s10875-024-01822-6.

394 21. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, Sohani M,
395 Shirmast P, Chavoshzadeh Z, Mahdaviani SA, Kalantari A, Tavakol M, Jabbari-Azad
396 F, Ahanchian H, Momen T, Sherkat R, Sadeghi-Shabestari M, Aleyasin S,
397 Esmaeilzadeh H, Al-Herz W, Bousfiha AA, Condino-Neto A, Seppanen M, Sullivan
398 KE, Hammarstrom L, Modell V, Modell F, Quinn J, Orange JS, Aghamohammadi A.
399 Global systematic review of primary immunodeficiency registries. *Expert Rev Clin*
400 *Immunol* 2020;**16**(7):717-32 doi: 10.1080/1744666X.2020.1801422.

401 22. Chapel H, Prevot J, Gaspar HB, Espanol T, Bonilla FA, Solis L, Drabwell J, Editorial
402 Board for Working Party on Principles of Care at I. Primary immune deficiencies -
403 principles of care. *Frontiers in immunology* 2014;**5**:627 doi:
404 10.3389/fimmu.2014.00627.

405 23. Kohler S, Gargano M, Matentzoglu N, Carmody LC, Lewis-Smith D, Vasilevsky NA,
406 Danis D, Balagura G, Baynam G, Brower AM, Callahan TJ, Chute CG, Est JL, Galer
407 PD, Ganesan S, Griese M, Haimel M, Pazmandi J, Hanauer M, Harris NL, Hartnett
408 MJ, Hastreiter M, Hauck F, He Y, Jeske T, Kearney H, Kindle G, Klein C, Knoflach K,
409 Krause R, Lagorce D, McMurry JA, Miller JA, Munoz-Torres MC, Peters RL, Rapp
410 CK, Rath AM, Rind SA, Rosenberg AZ, Segal MM, Seidel MG, Smedley D, Talmy T,
411 Thomas Y, Wiafe SA, Xian J, Yuksel Z, Helbig I, Mungall CJ, Haendel MA, Robinson
412 PN. The Human Phenotype Ontology in 2021. *Nucleic Acids Res*
413 2021;**49**(D1):D1207-D17 doi: 10.1093/nar/gkaa1043.

24. Haimel M, Pazmandi J, Heredia RJ, Dmytrus J, Bal SK, Zoghi S, van Daele P, Briggs TA, Wouters C, Bader-Meunier B, Aeschlimann FA, Caorsi R, Eleftheriou D, Hoppenreijs E, Salzer E, Bakhtiar S, Derfalvi B, Saettini F, Kusters MAA, Elfeky R, Truck J, Riviere JG, van der Burg M, Gattorno M, Seidel MG, Burns S, Warnatz K, Hauck F, Brogan P, Gilmour KC, Schuetz C, Simon A, Bock C, Hambleton S, de Vries E, Robinson P, van Gijn M, Boztug K. Curation and Expansion of Human Phenotype Ontology for Defined Groups of Inborn Errors of Immunity. *The Journal of allergy and clinical immunology* 2021 doi: 10.1016/j.jaci.2021.04.033.

25. Jacobsen JOB, Baudis M, Baynam GS, Beckmann JS, Beltran S, Buske OJ, Callahan TJ, Chute CG, Courtot M, Danis D, Elemento O, Essenwanger A, Freimuth RR, Gargano MA, Groza T, Hamosh A, Harris NL, Kaliyaperumal R, Lloyd KCK, Khalifa A, Krawitz PM, Kohler S, Laraway BJ, Lehvaslaiho H, Matalonga L, McMurry JA, Metke-Jimenez A, Mungall CJ, Munoz-Torres MC, Ogishima S, Papakonstantinou A, Piscia D, Pontikos N, Queralt-Rosinach N, Roos M, Sass J, Schofield PN, Seelow D, Siapos A, Smedley D, Smith LD, Steinhaus R, Sundaramurthi JC, Swietlik EM, Thun S, Vasilevsky NA, Wagner AH, Warner JL, Weiland C, Consortium GPM, Haendel MA, Robinson PN. The GA4GH Phenopacket schema defines a computable representation of clinical data. *Nat Biotechnol* 2022;**40**(6):817-20 doi: 10.1038/s41587-022-01357-4.

26. Danis D, Bamshad MJ, Bridges Y, Cacheiro P, Carmody LC, Chong JX, Coleman B, Dalgleish R, Freeman PJ, Graefe ASL, Groza T, Jacobsen JOB, Klocperk A, Kusters M, Ladewig MS, Marcello AJ, Mattina T, Mungall CJ, Munoz-Torres MC, Reese JT, Rehburg F, Reis BCS, Schuetz C, Smedley D, Strauss T, Sundaramurthi JC, Thun S, Wissink K, Wagstaff JF, Zocche D, Haendel MA, Robinson PN. A corpus of GA4GH Phenopackets: case-level phenotyping for genomic diagnostics and discovery. *medRxiv* 2024 doi: 10.1101/2024.05.29.24308104.